




*pharmaceuticals*

IMPACT  
FACTOR  
5.863

Indexed in:  
PubMed



# Slow Inhalation Enhances ProAir Delivery to the Lung

Volume 15 • Issue 6 | June 2022



mdpi.com/journal/pharmaceuticals  
ISSN 1424-8247

Sign In / Sign Up (/user/login)

Submit (<https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceuticals>)

**Search for Articles:**

Title / Keyword

Author / Affiliation / Email

Pharmaceuticals

All Article Types

**Search**

**Advanced Search**

[Journals \(/about/journals\)](#) / 
 [Pharmaceuticals \(/journal/pharmaceuticals\)](#) / 
 [Editorial Board \(/journal/pharmaceuticals/editors\)](#) / 
 Section 'Pharmacology' / 
 
[\( /journal/pharmaceuti](#)

IMPACT FACTOR  
5.215

Indexed in:  
PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/?term=1424-8247>)

Submit to *Pharmaceuticals* ([https://susy.mdpi.com/user/manuscripts/upload?form\[journal\\_id\]=18](https://susy.mdpi.com/user/manuscripts/upload?form[journal_id]=18))

Review for *Pharmaceuticals* (<https://susy.mdpi.com/volunteer/journals/review>)

**Journal Menu**

► **Journal Menu**

- [Pharmaceuticals Home \(/journal/pharmaceuticals\)](#)
- [Aims & Scope \(/journal/pharmaceuticals/about\)](#)
- [Editorial Board \(/journal/pharmaceuticals/editors\)](#)
- [Reviewer Board \(/journal/pharmaceuticals/submission\\_reviewers\)](#)
- [Topical Advisory Panel \(/journal/pharmaceuticals/topical\\_advisory\\_panel\)](#)
- [Instructions for Authors \(/journal/pharmaceuticals/instructions\)](#)
- [Special Issues \(/journal/pharmaceuticals/special\\_issues\)](#)
- [Topics \(/topics?query=&journal=pharmaceuticals&status=all&category=all\)](#)
- [Sections & Collections \(/journal/pharmaceuticals/sections\)](#)
- [Article Processing Charge \(/journal/pharmaceuticals/apc\)](#)
- [Indexing & Archiving \(/journal/pharmaceuticals/indexing\)](#)
- [Editor's Choice Articles \(/journal/pharmaceuticals/editors\\_choice\)](#)
- [Most Cited & Viewed \(/journal/pharmaceuticals/most\\_cited\)](#)
- [Journal Statistics \(/journal/pharmaceuticals/stats\)](#)
- [Journal History \(/journal/pharmaceuticals/history\)](#)
- [Journal Awards \(/journal/pharmaceuticals/awards\)](#)
- [Society Collaborations \(/journal/pharmaceuticals/societies\)](#)
- [Conferences \(/journal/pharmaceuticals/events\)](#)
- [Editorial Office \(/journal/pharmaceuticals/editorial\\_office\)](#)

**Journal Browser**

► **Journal Browser**

volume




issue

**Go**


- > [Forthcoming issue \(/1424-8247/16/4\)](#)
- > [Current issue \(/1424-8247/16/3\)](#)

- [Vol. 16 \(2023\) \(/1424-8247/16\)](#)
- [Vol. 15 \(2022\) \(/1424-8247/15\)](#)
- [Vol. 14 \(2021\) \(/1424-8247/14\)](#)
- [Vol. 13 \(2020\) \(/1424-8247/13\)](#)
- [Vol. 12 \(2019\) \(/1424-8247/12\)](#)
- [Vol. 11 \(2018\) \(/1424-8247/11\)](#)
- [Vol. 10 \(2017\) \(/1424-8247/10\)](#)
- [Vol. 9 \(2016\) \(/1424-8247/9\)](#)

Vol. 8 (2015). (/1424-8247/8)  
Vol. 7 (2014). (/1424-8247/7)  
Vol. 6 (2013). (/1424-8247/6)  
Vol. 5 (2012). (/1424-8247/5)  
Vol. 4 (2011). (/1424-8247/4)  
Vol. 3 (2010). (/1424-8247/3)  
Vol. 2 (2009). (/1424-8247/2)  
Vol. 1 (2004). (/1424-8247/1)

 [\(toggle desktop layout cookie\)](#)  

Affiliated Society:

 [https://serve.mdpi.com/www/my\\_files/cliik.php?oaparams=0&bannerid=7061&zoneid=4&cb=9770f0a7e7oadest=https%3A%2F%2Fwww.apsgb.co.uk](https://serve.mdpi.com/www/my_files/cliik.php?oaparams=0&bannerid=7061&zoneid=4&cb=9770f0a7e7oadest=https%3A%2F%2Fwww.apsgb.co.uk)

## Editorial Board for section 'Pharmacology'



- [Medicinal Chemistry Section \(/journal/pharmaceuticals/sectioneditors/pharm\\_medicinal\\_chemistry\)](/journal/pharmaceuticals/sectioneditors/pharm_medicinal_chemistry)
- [Biopharmaceuticals Section \(/journal/pharmaceuticals/sectioneditors/biopharmaceuticals\)](/journal/pharmaceuticals/sectioneditors/biopharmaceuticals)
- [Natural Products Section \(/journal/pharmaceuticals/sectioneditors/natural\\_products\)](/journal/pharmaceuticals/sectioneditors/natural_products)
- [Radiopharmaceutical Sciences Section \(/journal/pharmaceuticals/sectioneditors/radiopharmaceutical\\_sciences\)](/journal/pharmaceuticals/sectioneditors/radiopharmaceutical_sciences)
- [Pharmacology Section \(/journal/pharmaceuticals/sectioneditors/pharm-pharmacology\)](/journal/pharmaceuticals/sectioneditors/pharm-pharmacology)
- [Pharmaceutical Technology Section \(/journal/pharmaceuticals/sectioneditors/pharmaceutical\\_technology\)](/journal/pharmaceuticals/sectioneditors/pharmaceutical_technology)

Please see [the section webpage \(/journal/pharmaceuticals/sections/pharm-pharmacology\)](/journal/pharmaceuticals/sections/pharm-pharmacology) for more information on this section.

### Members (45)

Search by first name, last name, affiliation,



**Prof. Dr. Gary J. Stephens** (<https://sciprofiles.com/profile/43946>)

[Website \(https://www.reading.ac.uk/pharmacy/staff/professor-gary-stephens\)](https://www.reading.ac.uk/pharmacy/staff/professor-gary-stephens)

*Section Editor-in-Chief*

School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ, UK

**Interests:** electrophysiology; voltage-gated calcium channels; cannabinoids; ion channels; GPCRs; pain; ataxia

[Special Issues, Collections and Topics in MDPI journals](#)



**Dr. Raffaella Chiamonte** (<https://sciprofiles.com/profile/654244>)

[Website \(https://www.unimi.it/en/ugov/person/raffaella-chiamonte\)](https://www.unimi.it/en/ugov/person/raffaella-chiamonte)

*Editorial Board Member*

Department of Health Sciences, Università degli Studi di Milano, 20142 Milano, Italy

**Interests:** notch pathway; signal transduction, cancer cell biology; tumor microenvironment; extracellular vesicles.



**Dr. Dominique Massotte** (<https://sciprofiles.com/profile/718843>)

[Website \(https://www.researchgate.net/profile/Dominique-Massotte/2\)](https://www.researchgate.net/profile/Dominique-Massotte/2)

*Editorial Board Member*

French National Centre for Scientific Research, Institut des Neurosciences Cellulaires et Intégratives, University of Strasbourg, 67000 Strasbourg, France

**Interests:** opioid system; opioid receptors; G protein-coupled receptor trafficking and signaling; G protein-coupled receptor heteromerization; G protein-coupled receptor in addiction or chronic pain (preclinical models)

[Special Issues, Collections and Topics in MDPI journals](#)



**Prof. Dr. Paolo Arosio** (<https://sciprofiles.com/profile/149345>)

[Website \(https://www.researchgate.net/profile/Paolo\\_Arosio\)](https://www.researchgate.net/profile/Paolo_Arosio)

*Section Board Member*

Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

**Interests:** iron metabolism; ferritin; iron storage

[Special Issues, Collections and Topics in MDPI journals](#)

**Dr. Nektarios Barabutis** (<https://sciprofiles.com/profile/867285>)

[Website \(https://webservices.ulm.edu/facultyactivities/profile/barabutis\)](https://webservices.ulm.edu/facultyactivities/profile/barabutis)

*Section Board Member*

College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA

**Interests:** pathophysiology of acute lung injury and acute respiratory distress syndrome; P53 in the lung endothelium; unfolded protein response in the regulation of endothelial permeability; endoplasmic reticulum stress in the context of the lung microvasculature; heat shock proteins; extra hypothalamic effects of growth hormone-releasing hormone; endocrine-related cancer; reactive oxygen species; vascular biology

[Special Issues, Collections and Topics in MDPI journals](#)



**Prof. Dr. Simona Bertoni** (<https://sciprofiles.com/profile/769272>)

**Website** (<https://www.unipr.it/ugov/person/19178>)

*Section Board Member*

Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy

**Interests:** Pharmacology; intestinal inflammation; Eph-ephrin system; Eph-ephrin ligands; cholinergic receptors; mesenteric ischemia-reperfusion; serotonin and histamine ligands

**Special Issues, Collections and Topics in MDPI journals**



**Prof. Dr. Giuseppe Biagini** (<https://sciprofiles.com/profile/258520>)

**Website** (<http://personale.unimore.it/rubrica/dettaglio/gbiagini>)

*Section Board Member*

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy

**Interests:** animal ethics; animal welfare; epilepsy models; neuroprotection; stress management

**Special Issues, Collections and Topics in MDPI journals**



**Dr. Francesco Bifari** (<https://sciprofiles.com/profile/1253754>)

**Website** (<https://www.unimi.it/en/ugov/person/francesco-bifari>)

*Section Board Member*

Laboratory of Cell Metabolism and Regenerative Medicine, Department of Medical Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy

**Interests:** immune suppression; embryonic stem cells; mesenchymal stem cells; immunogenicity; regenerative medicine; neural stem cells



**Dr. Conor R. Caffrey** (<https://sciprofiles.com/profile/174040>)

**Website** (<https://pharmacy.ucsd.edu/faculty/bios/caffrey.shtml>)

*Section Board Member*

Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA

**Interests:** small molecule drug discovery for parasitic protozoa and helminths; 'neglected' tropical diseases; high-throughput and high content screening; proteolysis



**Prof. Dr. Márcia Carvalho** (<https://sciprofiles.com/profile/530291>)

**Website** (<https://www.cienciavita.pt/pt/8B10-171E-E63E>)

*Section Board Member*

Faculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 4200-150 Porto, Portugal

**Interests:** toxicology; drugs of abuse; amphetamines; synthetic cathinones; psychoactive substances; toxicometabolomics; cancer metabolomics; biomarkers; hepatotoxicity; nephrotoxicity; cardiotoxicity; oxidative stress

**Special Issues, Collections and Topics in MDPI journals**

**Prof. Dr. Abdeslam Chagraoui** (<https://sciprofiles.com/profile/661720>)

**Website** ([https://www.researchgate.net/profile/Abdeslam\\_Chagraoui](https://www.researchgate.net/profile/Abdeslam_Chagraoui))

*Section Board Member*

Department of Medical Biochemistry, Rouen University Hospital, 76000 Rouen, France

**Interests:** monoamines; neurochemistry; neuropharmacology; neuropsychopharmacology; mood disorders; addiction; Parkinson's disease and Schizophrenia

**Special Issues, Collections and Topics in MDPI journals**



**Prof. Dr. Jianguo Cheng**

**Website** (<https://www.lerner.ccf.org/neurosciences/cheng/>)

*Section Board Member*

Cleveland Clinic, Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH, USA

**Interests:** Neuropathic pain: mechanisms and therapeutics



**Prof. Dr. Réjean Couture** (<https://sciprofiles.com/profile/148870>)

**Website** (<https://pharmacologie-physiologie.umontreal.ca/recherche/chercheurs/rejean-couture/>)

*Section Board Member*

Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada

**Interests:** inflammation; pain neuropathy; diabetes; ocular diseases; epilepsy; Alzheimer disease



**Dr. Giorgio Cozza** (<https://sciprofiles.com/profile/223571>)

**Website** (<https://en.didattica.unipd.it/off/docente/1B8D2DEDCE85FDF7935A369A1EFEC6E6>)

Section Board Member

Department of Molecular Medicine, University of Padova, 35131 Padova, Italy

**Interests:** biochemistry and computational chemistry; cystic fibrosis; ferroptosis; lipid peroxidation; neurodegeneration; cancer research; protein phosphorylation; signal transduction; drug design and development; drug repurposing

[Special Issues, Collections and Topics in MDPI journals](#)



**Dr. Alessandra Durazzo** (<https://sciprofiles.com/profile/115749>)

**Website** (<https://www.researchgate.net/profile/Alessandra-Durazzo>)

Section Board Member

CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy

**Interests:** bioactive compounds; natural products; nutraceuticals; antioxidants; dietary supplements; food quality; nutrition; food composition databases; bioavailability, metabolic pathway; nanoformulations

[Special Issues, Collections and Topics in MDPI journals](#)



**Prof. Dr. Antoni Camins Espuny** (<https://sciprofiles.com/profile/367868>)

**Website1** (<http://www.neurociencias.ub.edu/antoni-camins-espuny/>) **Website2** (<https://ciberned.es/grupo-camins.html>) **Website3**

(<https://webgrec.ub.edu/webpages/000003/cas/camins.ub.edu.html>)

Section Board Member

1. Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
2. Institut de Neurociències, University of Barcelona, 08028 Barcelona, Spain
3. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Juan Carlos III, 28031 Madrid, Spain

**Interests:** Alzheimer's disease; aging; apoptosis; neuropharmacology; epilepsy

[Special Issues, Collections and Topics in MDPI journals](#)



**Dr. Marco Fiore** (<https://sciprofiles.com/profile/925152>)

**Website1** (<https://publons.com/researcher/1394914/marco-fiore/>) **Website2** (<https://orcid.org/0000-0001-7263-0229>)

Section Board Member

Dep. of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli" (Italy), Piazza Miraglia 2, 80138 Naples, Italy

**Interests:** life threatening infections; septic shock; spontaneous bacterial peritonitis; hepatology; infectious diseases

**Prof. Dr. Hiroyuki Fukui** (<https://sciprofiles.com/profile/435734>)

**Website** ([https://www.researchgate.net/profile/Hiroyuki\\_Fukui](https://www.researchgate.net/profile/Hiroyuki_Fukui))

Section Board Member

Department of Molecular Studies for Incurable Diseases, Tokushima University, Tokushima 770-0855, Japan

**Interests:** molecular pharmacology; anti-allergic; natural medicines; pathological mechanism of allergy; histamine h1 receptor

[Special Issues, Collections and Topics in MDPI journals](#)



**Prof. Dr. Ioanna Gouni-Berthold** (<https://sciprofiles.com/profile/92052>)

**Website** (<https://www.researchgate.net/profile/Ioanna-Gouni-Berthold>)

Section Board Member

Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Köln, Germany

**Interests:** medications modulating lipid metabolism; hyperlipoproteinemias; dyslipidemias; rare disorders of lipid metabolism; familial hypercholesterolemia; familial chylomicronemia

[Special Issues, Collections and Topics in MDPI journals](#)



**Dr. Raffaella Gozzelino** (<https://sciprofiles.com/profile/147880>)

**Website** (<http://cedoc.uni.pt/inflam-and-neurodeg/>)

Section Board Member

1. Chronic Disease Research Center (CEDOC)/NOVA Medical School, NOVA University of Lisbon, 1180-052, 1150-082 Lisbon, Portugal

2. Atlantic Technical University (UTA), Mindelo, São Vicente, CP 2110, Cabo Verde

**Interests:** gut microbiota; gut microbiome; iron metabolism; heme biology; inflammation; infections and neurodegeneration

[Special Issues, Collections and Topics in MDPI journals](#)



**Dr. Barbara Guerra** (<https://sciprofiles.com/profile/217294>)

**Website** (<https://portal.findresearcher.sdu.dk/en/persons/barbarag>)

Section Board Member

Dept. of Biochemistry and Molecular Biology, Section for Translational Biology, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark

**Interests:** cell cycle regulation; DNA damage response; cell signalling; protein kinases; kinase inhibitors; cancer; cardiac muscle cells biology



**Dr. Iain P. Hargreaves** (<https://sciprofiles.com/profile/284272>)

**Website** (<https://www.ljmu.ac.uk/about-us/staff-profiles/faculty-of-science/pharmacy-and-biomolecular-sciences/iain-hargreaves>)

Section Board Member

School of Pharmacy, John Moores University, Liverpool, UK

**Interests:** mitochondrial metabolism; coenzyme Q10; oxidative stress; antioxidants

**Special Issues, Collections and Topics in MDPI journals**

**Prof. Dr. Tsai-Ching Hsu** (<https://sciprofiles.com/profile/218905>)

**Website** (<https://medicine.csmu.edu.tw/p/405-1046-51129.c3717.php?Lang=zh-tw>)

Section Board Member

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

**Interests:** immunopharmacology; molecular and biochemical pharmacology; translational pharmacology/medicine

**Prof. Dr. Rina Hui**

**Website1** (<https://www.med.hku.hk/en/depts/teaching/sclinmed/Centre-of-Cancer-Medicine>) **Website2** (<https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/rina-hui.html>)

Section Board Member

1. Clinical Professor, Director of Centre of Cancer Medicine, University of Hong Kong, Hong Kong, China

2. Adjunct Professor, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia

**Interests:** breast cancer and lung cancer; immunotherapy



**Prof. Dr. Olaf-Georg Issinger** (<https://sciprofiles.com/profile/148867>)

**Website** ([http://findresearcher.sdu.dk/portal/en/persons/olafgeorg-issinger\(b2b69f82-6a5b-4085-9616-4bcc9d856517\).html](http://findresearcher.sdu.dk/portal/en/persons/olafgeorg-issinger(b2b69f82-6a5b-4085-9616-4bcc9d856517).html))

Section Board Member

Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark

**Interests:** cell biology; signal transduction; protein kinases; molecular pathology; cancer



**Dr. Supratik Kar** (<https://sciprofiles.com/profile/209339>)

**Website** (<https://scholar.google.com/citations?hl=en&user=kzGUHjYAAAAJ>)

Section Board Member

Assistant Professor, Chemometrics & Molecular Modeling Laboratory, Department of Chemistry, Kean University, Union, NJ, USA

**Interests:** cheminformatics; bioinformatics; molecular modeling; pharmacology and toxicology; pharmacy

**Dr. Woo-Yang Kim** (<https://sciprofiles.com/profile/1084841>)

**Website** (<https://www.kent.edu/biology/woo-yang-kim>)

Section Board Member

Department of Biological Sciences, Kent State University, Kent, OH 44242, USA

**Interests:** anxiety; depression; neuroprotection; mood disorder; autism; intellectual disability; neural regeneration; neurodegeneration; neural differentiation; drug screening



**Prof. Dr. Alberto Lazarowski** (<https://sciprofiles.com/profile/386810>)

**Website** (<https://scholar.google.com/citations?user=xCnUf0AAAAAJ&hl=es>)

Section Board Member

Clinical Biochemistry Department, Institute for Research in Physiopathology and Clinical Biochemistry (INFIBIOC), School of Pharmacy and Biochemistry (FFyB), University of Buenos Aires, Buenos Aires (UBA), Argentina

**Interests:** ABC-transporters; refractory epilepsy; Hypoxia; pharmacoresistance



**Dr. Hyo-Jong Lee** (<https://sciprofiles.com/profile/643043>)

**Website** ([https://skb.skku.edu/eng\\_pharm/intro/faculty\\_pharmacy.do](https://skb.skku.edu/eng_pharm/intro/faculty_pharmacy.do))

Section Board Member

School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea




**Interests:** molecular pathophysiology; pharmacology; vascular biology; tumor microenvironment; nutraceuticals

**Prof. Dr. Bertrand Liagre** (<https://sciprofiles.com/profile/253422>)

**Website** (<https://www.unilim.fr/labcis/annuaire/membres-du-theme-1/liagre-b/>)

Section Board Member

LABCiS UR 22722, Faculté de Pharmacie, Université de Limoges, 87000 Limoges, France

 [\(toggle desktop layout cookie\)](#)  

**Interests:** cancer; photodynamic therapy; apoptosis; cyclooxygenase-2

**Special Issues, Collections and Topics in MDPI journals**

Displaying Editorial board member 1-30 on page 1 of 2.

Go to page [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [21](#) [22](#) [23](#) [24](#) [25](#) [26](#) [27](#) [28](#) [29](#) [30](#)

**Pharmaceuticals** (</journal/pharmaceuticals>), EISSN 1424-8247, Published by MDPI

**RSS** (</rss/journal/pharmaceuticals>) **Content Alert** (</journal/pharmaceuticals/toc-alert>)

Further Information

**Article Processing Charges** (</apc>)

**Pay an Invoice** (</about/payment>)

**Open Access Policy** (</openaccess>)

**Contact MDPI** (</about/contact>)

**Jobs at MDPI** (<https://careers.mdpi.com>)

Guidelines

**For Authors** (</authors>)

**For Reviewers** (</reviewers>)

**For Editors** (</editors>)

**For Librarians** (</librarians>)

**For Publishers** ([/publishing\\_services](/publishing_services))

**For Societies** (</societies>)

**For Conference Organizers** ([/conference\\_organizers](/conference_organizers))

MDPI Initiatives

**Sciforum** (<https://sciforum.net>)

**MDPI Books** (<https://www.mdpi.com/books>)

**Preprints.org** (<https://www.preprints.org>)

**Scilit** (<https://www.scilit.net>)

**SciProfiles** (<https://sciprofiles.com>)

**Encyclopedia** (<https://encyclopedia.pub>)

**JAMS** (<https://jams.pub>)

**Proceedings Series** (</about/proceedings>)

Follow MDPI

**LinkedIn** (<https://www.linkedin.com/company/mdpi>)

**Facebook** (<https://www.facebook.com/MDPIOpenAccessPublishing>)

**Twitter** (<https://twitter.com/MDPIOpenAccess>)

Subscribe to receive issue release notifications and newsletters from MDPI journals

Select options

Enter your email address...

Subscribe

© 1996-2023 MDPI (Basel, Switzerland) unless otherwise stated

**Disclaimer** **Terms and Conditions** (</about/terms-and-conditions>) **Privacy Policy** (</about/privacy>)

[Sign In / Sign Up \(/user/login\)](#)[Submit \(https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceuticals\)](https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceuticals)

### Search for Articles:

### Advanced Search

[Journals \(/about/journals\)](#) / [Pharmaceuticals \(/journal/pharmaceuticals\)](#) / [Volume 15 \(/1424-8247/15\)](#) / [Issue 6 /](#)



**pharmaceuticals**

[\(/journal/pharmaceuti](#)



5.215



[Indexed in: PubMed \(https://www.ncbi.nlm.nih.gov/pubmed/?term=1424-8247\)](https://www.ncbi.nlm.nih.gov/pubmed/?term=1424-8247)

Submit to *Pharmaceuticals* ([https://susy.mdpi.com/user/manuscripts/upload?form\[journal\\_id\]=18](https://susy.mdpi.com/user/manuscripts/upload?form[journal_id]=18))

[Review for \*Pharmaceuticals\* \(https://susy.mdpi.com/volunteer/journals/review\)](https://susy.mdpi.com/volunteer/journals/review)

## Journal Menu

### ► Journal Menu

- [Pharmaceuticals Home \(/journal/pharmaceuticals\)](#)
- [Aims & Scope \(/journal/pharmaceuticals/about\)](#)
- [Editorial Board \(/journal/pharmaceuticals/editors\)](#)
- [Reviewer Board \(/journal/pharmaceuticals/submission\\_reviewers\)](#)
- [Topical Advisory Panel \(/journal/pharmaceuticals/topical\\_advisory\\_panel\)](#)
- [Instructions for Authors \(/journal/pharmaceuticals/instructions\)](#)
- [Special Issues \(/journal/pharmaceuticals/special\\_issues\)](#)
- [Topics \(/topics?query=&journal=pharmaceuticals&status=all&category=all\)](#)
- [Sections & Collections \(/journal/pharmaceuticals/sections\)](#)
- [Article Processing Charge \(/journal/pharmaceuticals/apc\)](#)
- [Indexing & Archiving \(/journal/pharmaceuticals/indexing\)](#)
- [Editor's Choice Articles \(/journal/pharmaceuticals/editors\\_choice\)](#)
- [Most Cited & Viewed \(/journal/pharmaceuticals/most\\_cited\)](#)
- [Journal Statistics \(/journal/pharmaceuticals/stats\)](#)
- [Journal History \(/journal/pharmaceuticals/history\)](#)
- [Journal Awards \(/journal/pharmaceuticals/awards\)](#)
- [Society Collaborations \(/journal/pharmaceuticals/societies\)](#)
- [Conferences \(/journal/pharmaceuticals/events\)](#)
- [Editorial Office \(/journal/pharmaceuticals/editorial\\_office\)](#)

## Journal Browser

### ► Journal Browser

> [Forthcoming issue \(/1424-8247/16/4\)](#)

> [Current issue \(/1424-8247/16/3\)](#)

[Vol. 16 \(2023\) \(/1424-8247/16\)](#)

[Vol. 15 \(2022\) \(/1424-8247/15\)](#)

[Vol. 14 \(2021\) \(/1424-8247/14\)](#)

[Vol. 13 \(2020\) \(/1424-8247/13\)](#)

[Vol. 12 \(2019\) \(/1424-8247/12\)](#)


[Vol. 11 \(2018\) \(/1424-8247/11\)](#)

[Vol. 10 \(2017\) \(/1424-8247/10\)](#)

[Vol. 9 \(2016\) \(/1424-8247/9\)](#)



## Pharmaceuticals, Volume 15, Issue 6 (June 2022) – 121 articles



**Cover Story** ([view full-size image \(/files/uploaded/covers/pharmaceuticals/big\\_cover-pharmaceuticals-v15-i6.png\)](#)): Many metered-dose inhaler (MDI) users with respiratory diseases cannot comply well with instructions and inhale differently during MDI actuation. A computational model was developed to investigate the pulmonary drug delivery from a ProAir MDI under varying inhalation depths. Experimental measurements were implemented as initial/boundary conditions for the spray aerosols from the actuator orifice. Remarkable differences were predicted in airflow dynamics and dosimetry in the MDI mouthpiece and oral cavity. Model cross-validation with existing experiments indicated a high dosimetry sensitivity to the initial spray properties (size and velocity) and transient inhalation rate. The results highlight the importance of personalized inhalation therapy to match patients' breathing patterns for optimal delivery efficiencies. [View this paper \(https://www.mdpi.com/1424-8247/15/6/706\)](https://www.mdpi.com/1424-8247/15/6/706)

<https://www.mdpi.com/1424-8247/15/6/706>

regarded as officially published after their release is announced to the [table of contents alert mailing list \(/journal/pharmaceuticals/toc-alert\)](#).

- You may [sign up for e-mail alerts \(/journal/pharmaceuticals/toc-alert\)](#) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free [Adobe Reader \(http://www.adobe.com/\)](http://www.adobe.com/) to open them.

### Order results

Publication Date

### Result details

Compact

### Section

All Sections

### Show export options

Open Access Review

[./1424-8247/15/6/767/pdf?version=1655793626](https://www.mdpi.com/1424-8247/15/6/767/pdf?version=1655793626)

### **The Potential Application of Natural Photosensitizers Used in Antimicrobial Photodynamic Therapy against Oral Infections (/1424-8247/15/6/767)**

*Pharmaceuticals* **2022**, *15*(6), 767; <https://doi.org/10.3390/ph15060767> (<https://doi.org/10.3390/ph15060767>) - 20 Jun 2022

Open Access Article

[./1424-8247/15/6/766/pdf?version=1655796376](https://www.mdpi.com/1424-8247/15/6/766/pdf?version=1655796376)

### **Inhibitors of O-Acetylserine Sulfhydrylase with a Cyclopropane-Carboxylic Acid Scaffold Are Effective Colistin Adjuvants in Gram Negative Bacteria (/1424-8247/15/6/766)**

*Pharmaceuticals* **2022**, *15*(6), 766; <https://doi.org/10.3390/ph15060766> (<https://doi.org/10.3390/ph15060766>) - 20 Jun 2022

Open Access Brief Report

[./1424-8247/15/6/765/pdf?version=1655805750](https://www.mdpi.com/1424-8247/15/6/765/pdf?version=1655805750)

### **Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs (/1424-8247/15/6/765)**

*Pharmaceuticals* **2022**, *15*(6), 765; <https://doi.org/10.3390/ph15060765> (<https://doi.org/10.3390/ph15060765>) - 20 Jun 2022

Open Access Systematic Review

[./1424-8247/15/6/764/pdf?version=1655801306](https://www.mdpi.com/1424-8247/15/6/764/pdf?version=1655801306)

### **Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review (/1424-8247/15/6/764)**

*Pharmaceuticals* **2022**, *15*(6), 764; <https://doi.org/10.3390/ph15060764> (<https://doi.org/10.3390/ph15060764>) - 19 Jun 2022

Open Access Article

[./1424-8247/15/6/763/pdf?version=1655546743](https://www.mdpi.com/1424-8247/15/6/763/pdf?version=1655546743)

### **Advanced Analytical Approach Based on Combination of FT-IR and Chemometrics for Quality Control of Pharmaceutical Preparations (/1424-8247/15/6/763)**

*Pharmaceuticals* **2022**, *15*(6), 763; <https://doi.org/10.3390/ph15060763> (<https://doi.org/10.3390/ph15060763>) - 18 Jun 2022

Open Access Review

[./1424-8247/15/6/762/pdf?version=1655794489](https://www.mdpi.com/1424-8247/15/6/762/pdf?version=1655794489)

### **A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development (/1424-8247/15/6/762)**

*Pharmaceuticals* **2022**, *15*(6), 762; <https://doi.org/10.3390/ph15060762> (<https://doi.org/10.3390/ph15060762>) - 18 Jun 2022

Open Access Article

[./1424-8247/15/6/761/pdf?version=1655538975](https://www.mdpi.com/1424-8247/15/6/761/pdf?version=1655538975)

### **Multi-Dose Intravenous Administration of Neutral and Cationic Liposomes in Mice: An Extensive Toxicity Study (/1424-8247/15/6/761)**

*Pharmaceuticals* **2022**, *15*(6), 761; <https://doi.org/10.3390/ph15060761> (<https://doi.org/10.3390/ph15060761>) - 18 Jun 2022

Open Access Article

[./1424-8247/15/6/760/pdf?version=1655947029](https://www.mdpi.com/1424-8247/15/6/760/pdf?version=1655947029)

### **Development of a Citric-Acid-Modified Cellulose Adsorbent Derived from *Moringa peregrina* Leaf for Adsorptive Removal of Citalopram HBr in Aqueous Solutions (/1424-8247/15/6/760)**






*Pharmaceuticals* **2022**, *15*(6), 760; <https://doi.org/10.3390/ph15060760> (<https://doi.org/10.3390/ph15060760>) - 17 Jun 2022

- Open Access Article    [.\(1424-8247/15/6/759/pdf?version=1655790031\)](https://doi.org/10.3390/ph15060759)
- Use of an Electronic Medication Management Support System in Patients with Polypharmacy in General Practice: A Quantitative Process Evaluation of the AdAM Trial (1424-8247/15/6/759)**
- Pharmaceuticals 2022, 15(6), 759; <https://doi.org/10.3390/ph15060759> (<https://doi.org/10.3390/ph15060759>) - 17 Jun 2022   
- 
- Open Access Article   [.\(1424-8247/15/6/758/pdf?version=1655792735\)](https://doi.org/10.3390/ph15060758) 
- Ginsenoside Rh3 Inhibits Lung Cancer Metastasis by Targeting Extracellular Signal-Regulated Kinase: A Network Pharmacology Study (1424-8247/15/6/758)**
- Pharmaceuticals 2022, 15(6), 758; <https://doi.org/10.3390/ph15060758> (<https://doi.org/10.3390/ph15060758>) - 17 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/757/pdf?version=1655782968\)](https://doi.org/10.3390/ph15060757)
- Effect of Norelgestromin and Ethinylestradiol in Transdermal Patches on the Clinical Outcomes and Biochemical Parameters of COVID-19 Patients: A Clinical Trial Pilot Study (1424-8247/15/6/757)**
- Pharmaceuticals 2022, 15(6), 757; <https://doi.org/10.3390/ph15060757> (<https://doi.org/10.3390/ph15060757>) - 17 Jun 2022
- 
- Open Access Editor's Choice Review   [.\(1424-8247/15/6/756/pdf?version=1655461062\)](https://doi.org/10.3390/ph15060756)
- Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production (1424-8247/15/6/756)**
- Pharmaceuticals 2022, 15(6), 756; <https://doi.org/10.3390/ph15060756> (<https://doi.org/10.3390/ph15060756>) - 17 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/755/pdf?version=1655386230\)](https://doi.org/10.3390/ph15060755)
- Development and Validation of an HPLC-UV Method for the Dissolution Studies of 3D-Printed Paracetamol Formulations in Milk-Containing Simulated Gastrointestinal Media (1424-8247/15/6/755)**
- Pharmaceuticals 2022, 15(6), 755; <https://doi.org/10.3390/ph15060755> (<https://doi.org/10.3390/ph15060755>) - 16 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/754/pdf?version=1655378525\)](https://doi.org/10.3390/ph15060754) 
- Quercetin-Rich Extracts from Onions (*Allium cepa*) Play Potent Cytotoxicity on Adrenocortical Carcinoma Cell Lines, and Quercetin Induces Important Anticancer Properties (1424-8247/15/6/754)**
- Pharmaceuticals 2022, 15(6), 754; <https://doi.org/10.3390/ph15060754> (<https://doi.org/10.3390/ph15060754>) - 16 Jun 2022
- 
- Open Access Review   [.\(1424-8247/15/6/753/pdf?version=1655379406\)](https://doi.org/10.3390/ph15060753)
- Pharmacological Induction of Fetal Hemoglobin in  $\beta$ -Thalassemia and Sickle Cell Disease: An Updated Perspective (1424-8247/15/6/753)**
- Pharmaceuticals 2022, 15(6), 753; <https://doi.org/10.3390/ph15060753> (<https://doi.org/10.3390/ph15060753>) - 16 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/752/pdf?version=1655880248\)](https://doi.org/10.3390/ph15060752) 
- Application of In Silico Filtering and Isothermal Titration Calorimetry for the Discovery of Small Molecule Inhibitors of MDM2 (1424-8247/15/6/752)**
- Pharmaceuticals 2022, 15(6), 752; <https://doi.org/10.3390/ph15060752> (<https://doi.org/10.3390/ph15060752>) - 16 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/751/pdf?version=1655369964\)](https://doi.org/10.3390/ph15060751) 
- The Synthesis, Characterization, Molecular Docking and In Vitro Antitumor Activity of Benzothiazole Aniline (BTA) Conjugated Metal-Salen Complexes as Non-Platinum Chemotherapeutic Agents (1424-8247/15/6/751)**
- Pharmaceuticals 2022, 15(6), 751; <https://doi.org/10.3390/ph15060751> (<https://doi.org/10.3390/ph15060751>) - 15 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/750/pdf?version=1655361848\)](https://doi.org/10.3390/ph15060750)
- Multifunctional Gel Films of Marine Polysaccharides Cross-Linked with Poly-Metal Ions for Wound Healing (1424-8247/15/6/750)**
- Pharmaceuticals 2022, 15(6), 750; <https://doi.org/10.3390/ph15060750> (<https://doi.org/10.3390/ph15060750>) - 15 Jun 2022
- 
- Open Access Systematic Review   [.\(1424-8247/15/6/749/pdf?version=1655364031\)](https://doi.org/10.3390/ph15060749) 
- Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review (1424-8247/15/6/749)**
- Pharmaceuticals 2022, 15(6), 749; <https://doi.org/10.3390/ph15060749> (<https://doi.org/10.3390/ph15060749>) - 14 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/748/pdf?version=1655954193\)](https://doi.org/10.3390/ph15060748) 
- Pharmacophore-Based Discovery of Viral RNA Conformational Modulators (1424-8247/15/6/748)**
- Pharmaceuticals 2022, 15(6), 748; <https://doi.org/10.3390/ph15060748> (<https://doi.org/10.3390/ph15060748>) - 14 Jun 2022
- 
- Open Access Editor's Choice Review   [.\(1424-8247/15/6/747/pdf?version=1655197691\)](https://doi.org/10.3390/ph15060747)
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis (1424-8247/15/6/747)**
- Pharmaceuticals 2022, 15(6), 747; <https://doi.org/10.3390/ph15060747> (<https://doi.org/10.3390/ph15060747>) - 14 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/746/pdf?version=1655196185\)](https://doi.org/10.3390/ph15060746) 
- L-Asparaginase from *Penicillium sizovae* Produced by a Recombinant *Komagataella phaffii* Strain (1424-8247/15/6/746)**
- Pharmaceuticals 2022, 15(6), 746; <https://doi.org/10.3390/ph15060746> (<https://doi.org/10.3390/ph15060746>) - 14 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/745/pdf?version=1655195966\)](https://doi.org/10.3390/ph15060745) 
- Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures (1424-8247/15/6/745)**
- Pharmaceuticals 2022, 15(6), 745; <https://doi.org/10.3390/ph15060745> (<https://doi.org/10.3390/ph15060745>) - 14 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/744/pdf?version=1655862177\)](https://doi.org/10.3390/ph15060744) 
- Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L (1424-8247/15/6/744)**
- Pharmaceuticals 2022, 15(6), 744; <https://doi.org/10.3390/ph15060744> (<https://doi.org/10.3390/ph15060744>) - 13 Jun 2022
- 
- Open Access Article   [.\(1424-8247/15/6/743/pdf?version=1655122682\)](https://doi.org/10.3390/ph15060743)

**In Vivo and In Vitro Antioxidant Activity of Less Polar Fractions of *Dasycladus vermicularis* (Scopoli) Krasser 1898 and the Chemical Composition of Fractions and Macroliga Volatilome** (1424-8247/15/6/743)

Pharmaceuticals 2022, 15(6), 743; <https://doi.org/10.3390/ph15060743> (<https://doi.org/10.3390/ph15060743>) - 13 Jun 2022


Open Access Article

    
 [./\(1424-8247/15/6/742/pdf?version=1655861892\)](#) 

**Longitudinal Consumption of Ergothioneine Reduces Oxidative Stress and Amyloid Plaques and Restores Glucose Metabolism in the 5XFAD Mouse Model of Alzheimer's Disease** (1424-8247/15/6/742)

Pharmaceuticals 2022, 15(6), 742; <https://doi.org/10.3390/ph15060742> (<https://doi.org/10.3390/ph15060742>) - 13 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/741/pdf?version=1655966516\)](#)

**Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System** (1424-8247/15/6/741)

Pharmaceuticals 2022, 15(6), 741; <https://doi.org/10.3390/ph15060741> (<https://doi.org/10.3390/ph15060741>) - 13 Jun 2022


Open Access Article

 [./\(1424-8247/15/6/740/pdf?version=1655111401\)](#)

**Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists** (1424-8247/15/6/740)

Pharmaceuticals 2022, 15(6), 740; <https://doi.org/10.3390/ph15060740> (<https://doi.org/10.3390/ph15060740>) - 13 Jun 2022


Open Access Review

 [./\(1424-8247/15/6/739/pdf?version=1655110196\)](#)

**Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?** (1424-8247/15/6/739)

Pharmaceuticals 2022, 15(6), 739; <https://doi.org/10.3390/ph15060739> (<https://doi.org/10.3390/ph15060739>) - 13 Jun 2022


Open Access Review

 [./\(1424-8247/15/6/738/pdf?version=1655858277\)](#)

**Target Therapies for Systemic Mastocytosis: An Update** (1424-8247/15/6/738)

Pharmaceuticals 2022, 15(6), 738; <https://doi.org/10.3390/ph15060738> (<https://doi.org/10.3390/ph15060738>) - 11 Jun 2022

Open Access Review

 [./\(1424-8247/15/6/737/pdf?version=1655171470\)](#)

**Sirtuins and Hypoxia in EMT Control** (1424-8247/15/6/737)

Pharmaceuticals 2022, 15(6), 737; <https://doi.org/10.3390/ph15060737> (<https://doi.org/10.3390/ph15060737>) - 10 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/736/pdf?version=1654860608\)](#) 

**Tigecycline and Gentamicin-Combined Treatment Enhances Renal Damage: Oxidative Stress, Inflammatory Reaction, and Apoptosis Interplay** (1424-8247/15/6/736)

Pharmaceuticals 2022, 15(6), 736; <https://doi.org/10.3390/ph15060736> (<https://doi.org/10.3390/ph15060736>) - 10 Jun 2022



Open Access Article

 [./\(1424-8247/15/6/735/pdf?version=1654857614\)](#)

**Antioxidant and Antibacterial Activity of *Helichrysum italicum* (Roth) G. Don. from Central Europe** (1424-8247/15/6/735)

Pharmaceuticals 2022, 15(6), 735; <https://doi.org/10.3390/ph15060735> (<https://doi.org/10.3390/ph15060735>) - 10 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/734/pdf?version=1655111743\)](#) 

**HIF-PH Encoded by *EGLN1* Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia** (1424-8247/15/6/734)

Pharmaceuticals 2022, 15(6), 734; <https://doi.org/10.3390/ph15060734> (<https://doi.org/10.3390/ph15060734>) - 10 Jun 2022



Open Access Article

 [./\(1424-8247/15/6/733/pdf?version=1654847544\)](#) 

**Sesamol Loaded Albumin Nanoparticles: A Boosted Protective Property in Animal Models of Oxidative Stress** (1424-8247/15/6/733)

Pharmaceuticals 2022, 15(6), 733; <https://doi.org/10.3390/ph15060733> (<https://doi.org/10.3390/ph15060733>) - 10 Jun 2022



Open Access Article

 [./\(1424-8247/15/6/732/pdf?version=1654852043\)](#) 

**The Use of Endo-Cellulase and Endo-Xylanase for the Extraction of Apple Pectins as Factors Modifying Their Anticancer Properties and Affecting Their Synergy with the Active Form of Irinotecan** (1424-8247/15/6/732)

Pharmaceuticals 2022, 15(6), 732; <https://doi.org/10.3390/ph15060732> (<https://doi.org/10.3390/ph15060732>) - 09 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/731/pdf?version=1655110169\)](#) 

**Impact of the Gram-Negative-Selective Inhibitor MAC13243 on In Vitro Simulated Gut Microbiota** (1424-8247/15/6/731)

Pharmaceuticals 2022, 15(6), 731; <https://doi.org/10.3390/ph15060731> (<https://doi.org/10.3390/ph15060731>) - 09 Jun 2022


Open Access Article

 [./\(1424-8247/15/6/730/pdf?version=1654766282\)](#) 

**A Comparative Study of the Pharmaceutical Properties between Amorphous Drugs Loaded-Mesoporous Silica and Pure Amorphous Drugs Prepared by Solvent Evaporation** (1424-8247/15/6/730)

Pharmaceuticals 2022, 15(6), 730; <https://doi.org/10.3390/ph15060730> (<https://doi.org/10.3390/ph15060730>) - 09 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/729/pdf?version=1654748138\)](#)

**<sup>99m</sup>Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities** (1424-8247/15/6/729)

Pharmaceuticals 2022, 15(6), 729; <https://doi.org/10.3390/ph15060729> (<https://doi.org/10.3390/ph15060729>) - 09 Jun 2022

Open Access Article

 [./\(1424-8247/15/6/728/pdf?version=1654697424\)](#) 

**Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer** (1424-8247/15/6/728)

Pharmaceuticals 2022, 15(6), 728; <https://doi.org/10.3390/ph15060728> (<https://doi.org/10.3390/ph15060728>) - 08 Jun 2022

Open Access Article



 [./\(1424-8247/15/6/727/pdf?version=1654671225\)](#)

**Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation** (1424-8247/15/6/727)

Pharmaceuticals 2022, 15(6), 727; <https://doi.org/10.3390/ph15060727> (<https://doi.org/10.3390/ph15060727>) - 08 Jun 2022

MDPI

Open Access Article

  [./\(1424-8247/15/6/726/pdf?version=1655739418\)](#)

**[6]-Shogaol Attenuates Oxaliplatin-Induced Allodynia through Serotonergic Receptors and GABA in the Spinal Cord in Mice** ([./\(1424-8247/15/6/726\)](#))  

Pharmaceuticals 2022, 15(6), 726; <https://doi.org/10.3390/ph15060726> (<https://doi.org/10.3390/ph15060726>) - 08 Jun 2022



Open Access Communication

  [./\(1424-8247/15/6/725/pdf?version=1655262264\)](#) 

**A New Chalcone and Antimicrobial Chemical Constituents of *Dracaena stedneuri*** ([./\(1424-8247/15/6/725\)](#))

Pharmaceuticals 2022, 15(6), 725; <https://doi.org/10.3390/ph15060725> (<https://doi.org/10.3390/ph15060725>) - 07 Jun 2022


Open Access Article

  [./\(1424-8247/15/6/724/pdf?version=1655132791\)](#)

**Purification, Characterization and Evaluation of the Antitumoral Activity of a Phospholipase A2 from the Snake *Bothrops moojeni*** ([./\(1424-8247/15/6/724\)](#))

Pharmaceuticals 2022, 15(6), 724; <https://doi.org/10.3390/ph15060724> (<https://doi.org/10.3390/ph15060724>) - 07 Jun 2022



Open Access Article

  [./\(1424-8247/15/6/723/pdf?version=1654592264\)](#) 

**Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets** ([./\(1424-8247/15/6/723\)](#))

Pharmaceuticals 2022, 15(6), 723; <https://doi.org/10.3390/ph15060723> (<https://doi.org/10.3390/ph15060723>) - 07 Jun 2022

Open Access Article

  [./\(1424-8247/15/6/722/pdf?version=1654585988\)](#)

**Combination of Photodynamic Therapy and Oral Antifungals for the Treatment of Onychomycosis** ([./\(1424-8247/15/6/722\)](#))

Pharmaceuticals 2022, 15(6), 722; <https://doi.org/10.3390/ph15060722> (<https://doi.org/10.3390/ph15060722>) - 07 Jun 2022



Open Access Article

  [./\(1424-8247/15/6/721/pdf?version=1654572312\)](#) 

**Design and Synthesis of a Mitochondria-Targeting Radioprotectant for Promoting Skin Wound Healing Combined with Ionizing Radiation Injury** ([./\(1424-8247/15/6/721\)](#))

Pharmaceuticals 2022, 15(6), 721; <https://doi.org/10.3390/ph15060721> (<https://doi.org/10.3390/ph15060721>) - 06 Jun 2022



Open Access Article

  [./\(1424-8247/15/6/720/pdf?version=1655180109\)](#)

**Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury** ([./\(1424-8247/15/6/720\)](#))

Pharmaceuticals 2022, 15(6), 720; <https://doi.org/10.3390/ph15060720> (<https://doi.org/10.3390/ph15060720>) - 06 Jun 2022



Open Access Editor's Choice Article

  [./\(1424-8247/15/6/719/pdf?version=1655259087\)](#)

**Adrenomedullin Improves Cardiac Remodeling and Function in Obese Rats with Hypertension** ([./\(1424-8247/15/6/719\)](#))

Pharmaceuticals 2022, 15(6), 719; <https://doi.org/10.3390/ph15060719> (<https://doi.org/10.3390/ph15060719>) - 06 Jun 2022



Open Access Article

  [./\(1424-8247/15/6/718/pdf?version=1654524098\)](#)

**Enhanced Thrombin Generation Is Associated with Worse Left Ventricular Scarring after ST-Segment Elevation Myocardial Infarction: A Cohort Study** ([./\(1424-8247/15/6/718\)](#))

Pharmaceuticals 2022, 15(6), 718; <https://doi.org/10.3390/ph15060718> (<https://doi.org/10.3390/ph15060718>) - 06 Jun 2022

Open Access Review

  [./\(1424-8247/15/6/717/pdf?version=1655114131\)](#)

**The Diverse Biological Activity of Recently Synthesized Nitro Compounds** ([./\(1424-8247/15/6/717\)](#))

Pharmaceuticals 2022, 15(6), 717; <https://doi.org/10.3390/ph15060717> (<https://doi.org/10.3390/ph15060717>) - 05 Jun 2022

Open Access Article

  [./\(1424-8247/15/6/716/pdf?version=1654677205\)](#) 

**Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo** ([./\(1424-8247/15/6/716\)](#))

Pharmaceuticals 2022, 15(6), 716; <https://doi.org/10.3390/ph15060716> (<https://doi.org/10.3390/ph15060716>) - 05 Jun 2022

Open Access Article

  [./\(1424-8247/15/6/715/pdf?version=1654413376\)](#) 

**Antistaphylococcal Activities and ADME-Related Properties of Chlorinated Arylcarbamoylnaphthalenylcarbamates** ([./\(1424-8247/15/6/715\)](#))

Pharmaceuticals 2022, 15(6), 715; <https://doi.org/10.3390/ph15060715> (<https://doi.org/10.3390/ph15060715>) - 05 Jun 2022



Open Access Editor's Choice Article

  [./\(1424-8247/15/6/714/pdf?version=1654594054\)](#) 

**Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators** ([./\(1424-8247/15/6/714\)](#))

Pharmaceuticals 2022, 15(6), 714; <https://doi.org/10.3390/ph15060714> (<https://doi.org/10.3390/ph15060714>) - 04 Jun 2022

Open Access Article

  [./\(1424-8247/15/6/713/pdf?version=1654511827\)](#)

**Safety of Antibiotics in Hospitalized Children in Romania: A Prospective Observational Study** ([./\(1424-8247/15/6/713\)](#))

Pharmaceuticals 2022, 15(6), 713; <https://doi.org/10.3390/ph15060713> (<https://doi.org/10.3390/ph15060713>) - 03 Jun 2022

Open Access Article

  [./\(1424-8247/15/6/712/pdf?version=1654267556\)](#) 

**Synthesis of Coumarin and Homoisoflavonoid Derivatives and Analogs: The Search for New Antifungal Agents** ([./\(1424-8247/15/6/712\)](#))

Pharmaceuticals 2022, 15(6), 712; <https://doi.org/10.3390/ph15060712> (<https://doi.org/10.3390/ph15060712>) - 03 Jun 2022



Open Access Review

  [./\(1424-8247/15/6/711/pdf?version=1655080413\)](#)

**High-Dose Vitamin C for Cancer Therapy** ([./\(1424-8247/15/6/711\)](#))

Pharmaceuticals 2022, 15(6), 711; <https://doi.org/10.3390/ph15060711> (<https://doi.org/10.3390/ph15060711>) - 03 Jun 2022



Open Access Article

  [./\(1424-8247/15/6/710/pdf?version=1654590359\)](#)

**Mepirapim, a Novel Synthetic Cannabinoid, Induces Addiction-Related Behaviors through Neurochemical Maladaptation in the Brain of Rodents (1424-8247/15/6/710)**

Pharmaceuticals 2022, 15(6), 710; <https://doi.org/10.3390/ph15060710> (<https://doi.org/10.3390/ph15060710>) - 03 Jun 2022



Open Access Article

  [.\(toggle\\_desktop\\_layout\\_cookie\)](#)  

**Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans (1424-8247/15/6/709)**

Pharmaceuticals 2022, 15(6), 709; <https://doi.org/10.3390/ph15060709> (<https://doi.org/10.3390/ph15060709>) - 03 Jun 2022



Open Access Review

  [.\(1424-8247/15/6/709/pdf?version=1654677235\)](#)

**Focusing on Future Applications and Current Challenges of Plant Derived Extracellular Vesicles (1424-8247/15/6/708)**

Pharmaceuticals 2022, 15(6), 708; <https://doi.org/10.3390/ph15060708> (<https://doi.org/10.3390/ph15060708>) - 03 Jun 2022



Open Access Article

  [.\(1424-8247/15/6/708/pdf?version=1654253410\)](#)

**MPMABP: A CNN and Bi-LSTM-Based Method for Predicting Multi-Activities of Bioactive Peptides (1424-8247/15/6/707)**

Pharmaceuticals 2022, 15(6), 707; <https://doi.org/10.3390/ph15060707> (<https://doi.org/10.3390/ph15060707>) - 03 Jun 2022



Open Access Editor's Choice Article

  [.\(1424-8247/15/6/707/pdf?version=1654251293\)](#)

**Lower Inspiratory Breathing Depth Enhances Pulmonary Delivery Efficiency of ProAir Sprays (1424-8247/15/6/706)**

Pharmaceuticals 2022, 15(6), 706; <https://doi.org/10.3390/ph15060706> (<https://doi.org/10.3390/ph15060706>) - 03 Jun 2022



Open Access Review

  [.\(1424-8247/15/6/706/pdf?version=1654654522\)](#)

**Recent Progress in the Synthesis of Drugs and Bioactive Molecules Incorporating Nitro(het)arene Core (1424-8247/15/6/705)**

Pharmaceuticals 2022, 15(6), 705; <https://doi.org/10.3390/ph15060705> (<https://doi.org/10.3390/ph15060705>) - 03 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/705/pdf?version=1654501175\)](#)

**Assessing Gene Expression Related to Cisplatin Resistance in Human Oral Squamous Cell Carcinoma Cell Lines (1424-8247/15/6/704)**

Pharmaceuticals 2022, 15(6), 704; <https://doi.org/10.3390/ph15060704> (<https://doi.org/10.3390/ph15060704>) - 03 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/704/pdf?version=1654653546\)](#) 

**Nano-Silica Carriers Coated by Chloramphenicol: Synthesis, Characterization, and Grinding Trial as a Way to Improve the Release Profile (1424-8247/15/6/703)**

Pharmaceuticals 2022, 15(6), 703; <https://doi.org/10.3390/ph15060703> (<https://doi.org/10.3390/ph15060703>) - 02 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/703/pdf?version=1654173508\)](#) 

**Identification of Angiogenic Cargoes in Human Fibroblasts-Derived Extracellular Vesicles and Induction of Wound Healing (1424-8247/15/6/702)**

Pharmaceuticals 2022, 15(6), 702; <https://doi.org/10.3390/ph15060702> (<https://doi.org/10.3390/ph15060702>) - 02 Jun 2022



Open Access Article

  [.\(1424-8247/15/6/702/pdf?version=1654172843\)](#) 

**Low-Energy Electron Induced Reactions in Metronidazole at Different Solvation Conditions (1424-8247/15/6/701)**

Pharmaceuticals 2022, 15(6), 701; <https://doi.org/10.3390/ph15060701> (<https://doi.org/10.3390/ph15060701>) - 02 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/701/pdf?version=1654170738\)](#)

**In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers (1424-8247/15/6/700)**

Pharmaceuticals 2022, 15(6), 700; <https://doi.org/10.3390/ph15060700> (<https://doi.org/10.3390/ph15060700>) - 02 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/699/pdf?version=1654164043\)](#) 

**In Vitro Evaluation of the Antioxidant Activity and Chemopreventive Potential in Human Breast Cancer Cell Lines of the Standardized Extract Obtained from the Aerial Parts of Zigzag Clover (*Trifolium medium* L.) (1424-8247/15/6/699)**

Pharmaceuticals 2022, 15(6), 699; <https://doi.org/10.3390/ph15060699> (<https://doi.org/10.3390/ph15060699>) - 02 Jun 2022

Open Access Communication

  [.\(1424-8247/15/6/698/pdf?version=1654150837\)](#) 

**Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer (1424-8247/15/6/698)**

Pharmaceuticals 2022, 15(6), 698; <https://doi.org/10.3390/ph15060698> (<https://doi.org/10.3390/ph15060698>) - 02 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/697/pdf?version=1654084291\)](#) 

**Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe (1424-8247/15/6/697)**

Pharmaceuticals 2022, 15(6), 697; <https://doi.org/10.3390/ph15060697> (<https://doi.org/10.3390/ph15060697>) - 01 Jun 2022



Open Access Article

  [.\(1424-8247/15/6/696/pdf?version=1654079752\)](#)

**Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic Acid-Metabolizing Genes in the Mouse Lungs (1424-8247/15/6/696)**

Pharmaceuticals 2022, 15(6), 696; <https://doi.org/10.3390/ph15060696> (<https://doi.org/10.3390/ph15060696>) - 01 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/695/pdf?version=1654078754\)](#)

**A More Biomimetic Cell Migration Assay with High Reliability and Its Applications (1424-8247/15/6/695)**

Pharmaceuticals 2022, 15(6), 695; <https://doi.org/10.3390/ph15060695> (<https://doi.org/10.3390/ph15060695>) - 01 Jun 2022

Open Access Article

  [.\(1424-8247/15/6/694/pdf?version=1655877938\)](#) 

**Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections (1424-8247/15/6/694)**

Pharmaceuticals 2022, 15(6), 694; <https://doi.org/10.3390/ph15060694> (<https://doi.org/10.3390/ph15060694>) - 01 Jun 2022

Open Access Review

  [.\(1424-8247/15/6/693/pdf?version=1654136790\)](#)

**Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics (1424-8247/15/6/693)**

Pharmaceuticals 2022, 15(6), 693; <https://doi.org/10.3390/ph15060693> (<https://doi.org/10.3390/ph15060693>) - 01 Jun 2022

Open Access Review

  [./\(1424-8247/15/6/693/pdf?version=1654156845\)](#) 

**A Pivotal Role of Nrf2 in Neurodegenerative Disorders: A New Way for Therapeutic Strategies (1424-8247/15/6/692)**

Pharmaceuticals 2022, 15(6), 692; <https://doi.org/10.3390/ph15060692> (<https://doi.org/10.3390/ph15060692>) - 31 May 2022

Open Access Article

  [./\(1424-8247/15/6/691/pdf?version=1654065289\)](#) 

**In Silico Prediction of Plasmodium falciparum Cytoadherence Inhibitors That Disrupt Interaction between gC1qR-DBL $\beta$ 12 Complex (1424-8247/15/6/691)**

Pharmaceuticals 2022, 15(6), 691; <https://doi.org/10.3390/ph15060691> (<https://doi.org/10.3390/ph15060691>) - 31 May 2022




Open Access Article

  [./\(1424-8247/15/6/690/pdf?version=1654074674\)](#) 

**Dihydropyrazole-Carbohydrazone Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6 (1424-8247/15/6/690)**

Pharmaceuticals 2022, 15(6), 690; <https://doi.org/10.3390/ph15060690> (<https://doi.org/10.3390/ph15060690>) - 31 May 2022

Open Access Article

  [./\(1424-8247/15/6/689/pdf?version=1654151021\)](#) 

**Size-Dependent Antibacterial, Antidiabetic, and Toxicity of Silver Nanoparticles Synthesized Using Solvent Extraction of Rosa indica L. Petals (1424-8247/15/6/689)**

Pharmaceuticals 2022, 15(6), 689; <https://doi.org/10.3390/ph15060689> (<https://doi.org/10.3390/ph15060689>) - 31 May 2022

Open Access Article

  [./\(1424-8247/15/6/688/pdf?version=1653995844\)](#) 

**Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids (1424-8247/15/6/688)**

Pharmaceuticals 2022, 15(6), 688; <https://doi.org/10.3390/ph15060688> (<https://doi.org/10.3390/ph15060688>) - 31 May 2022

Open Access Article

  [./\(1424-8247/15/6/687/pdf?version=1653996331\)](#) 

**In Silico Antiprotozoal Evaluation of 1,4-Naphthoquinone Derivatives against Chagas and Leishmaniasis Diseases Using QSAR, Molecular Docking, and ADME Approaches (1424-8247/15/6/687)**

Pharmaceuticals 2022, 15(6), 687; <https://doi.org/10.3390/ph15060687> (<https://doi.org/10.3390/ph15060687>) - 31 May 2022

Open Access Article

  [./\(1424-8247/15/6/686/pdf?version=1654588554\)](#) 

**Exorbitant Drug Loading of Metformin and Sitagliptin in Mucoadhesive Buccal Tablet: In Vitro and In Vivo Characterization in Healthy Volunteers (1424-8247/15/6/686)**

Pharmaceuticals 2022, 15(6), 686; <https://doi.org/10.3390/ph15060686> (<https://doi.org/10.3390/ph15060686>) - 30 May 2022

Open Access Editor's Choice Review

  [./\(1424-8247/15/6/685/pdf?version=1654140022\)](#) 

**Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging (1424-8247/15/6/685)**

Pharmaceuticals 2022, 15(6), 685; <https://doi.org/10.3390/ph15060685> (<https://doi.org/10.3390/ph15060685>) - 30 May 2022

Open Access Article

  [./\(1424-8247/15/6/684/pdf?version=1655961855\)](#) 

**Discovery of a Multifunctional Octapeptide from Lingzhi with Antioxidant and Tyrosinase Inhibitory Activity (1424-8247/15/6/684)**

Pharmaceuticals 2022, 15(6), 684; <https://doi.org/10.3390/ph15060684> (<https://doi.org/10.3390/ph15060684>) - 30 May 2022

Open Access Article

  [./\(1424-8247/15/6/683/pdf?version=1653960918\)](#) 

**Bacterial Cellulose—Adaptation of a Nature-Identical Material to the Needs of Advanced Chronic Wound Care (1424-8247/15/6/683)**

Pharmaceuticals 2022, 15(6), 683; <https://doi.org/10.3390/ph15060683> (<https://doi.org/10.3390/ph15060683>) - 30 May 2022




Open Access Article

  [./\(1424-8247/15/6/682/pdf?version=1654659989\)](#) 

**Enhancing Colistin Activity against Colistin-Resistant Escherichia coli through Combination with Alginate Nanoparticles and Small Molecules (1424-8247/15/6/682)**

Pharmaceuticals 2022, 15(6), 682; <https://doi.org/10.3390/ph15060682> (<https://doi.org/10.3390/ph15060682>) - 28 May 2022

Open Access Opinion

  [./\(1424-8247/15/6/681/pdf?version=1653733945\)](#) 

**Clinical Utility of Medication-Based Risk Scores to Reduce Polypharmacy and Potentially Avoidable Healthcare Utilization (1424-8247/15/6/681)**

Pharmaceuticals 2022, 15(6), 681; <https://doi.org/10.3390/ph15060681> (<https://doi.org/10.3390/ph15060681>) - 28 May 2022

Open Access Article

  [./\(1424-8247/15/6/680/pdf?version=1654846918\)](#) 

**In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist (1424-8247/15/6/680)**

Pharmaceuticals 2022, 15(6), 680; <https://doi.org/10.3390/ph15060680> (<https://doi.org/10.3390/ph15060680>) - 28 May 2022




Open Access Article

  [./\(1424-8247/15/6/679/pdf?version=1654135504\)](#) 

**Design, Synthesis, In Vitro Biological Activity Evaluation and Stabilized Nanostructured Lipid Carrier Formulation of Newly Synthesized Schiff Bases-Based TMP Moieties (1424-8247/15/6/679)**

Pharmaceuticals 2022, 15(6), 679; <https://doi.org/10.3390/ph15060679> (<https://doi.org/10.3390/ph15060679>) - 28 May 2022




Open Access Review

  [./\(1424-8247/15/6/678/pdf?version=1654136040\)](#) 

**Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives (1424-8247/15/6/678)**

Pharmaceuticals 2022, 15(6), 678; <https://doi.org/10.3390/ph15060678> (<https://doi.org/10.3390/ph15060678>) - 27 May 2022

Open Access Article

  [./\(1424-8247/15/6/677/pdf?version=1653894543\)](#) 

**European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events (1424-8247/15/6/677)**

Pharmaceuticals 2022, 15(6), 677; <https://doi.org/10.3390/ph15060677> (<https://doi.org/10.3390/ph15060677>) - 27 May 2022

MDPI

Open Access Article

 [./\(1424-8247/15/6/676/pdf?version=1654050482\)](#) 

**Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MR16, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies** ([/1424-8247/15/6/676](#))

Pharmaceuticals 2022, 15(6), 676; <https://doi.org/10.3390/ph15060676> (<https://doi.org/10.3390/ph15060676>) - 27 May 2022

Open Access Article

 [./\(1424-8247/15/6/675/pdf?version=1653646969\)](#) 

**Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)** ([/1424-8247/15/6/675](#))

Pharmaceuticals 2022, 15(6), 675; <https://doi.org/10.3390/ph15060675> (<https://doi.org/10.3390/ph15060675>) - 27 May 2022

Open Access Article

 [./\(1424-8247/15/6/674/pdf?version=1654149406\)](#) 

**Protective Effect of Pycnogenol against Methotrexate-Induced Hepatic, Renal, and Cardiac Toxicity: An In Vivo Study** ([/1424-8247/15/6/674](#))

Pharmaceuticals 2022, 15(6), 674; <https://doi.org/10.3390/ph15060674> (<https://doi.org/10.3390/ph15060674>) - 27 May 2022



Open Access Article

 [./\(1424-8247/15/6/673/pdf?version=1653908012\)](#) 

**Design, Synthesis, and In Vitro, In Silico and In Cellulo Evaluation of New Pyrimidine and Pyridine Amide and Carbamate Derivatives as Multi-Functional Cholinesterase Inhibitors** ([/1424-8247/15/6/673](#))

Pharmaceuticals 2022, 15(6), 673; <https://doi.org/10.3390/ph15060673> (<https://doi.org/10.3390/ph15060673>) - 27 May 2022



Open Access Article

 [./\(1424-8247/15/6/672/pdf?version=1653903608\)](#) 

**Bio-Oriented Synthesis of Novel (S)-Flurbiprofen Clubbed Hydrazone Schiff's Bases for Diabetic Management: In Vitro and In Silico Studies** ([/1424-8247/15/6/672](#))

Pharmaceuticals 2022, 15(6), 672; <https://doi.org/10.3390/ph15060672> (<https://doi.org/10.3390/ph15060672>) - 27 May 2022



Open Access Article

 [./\(1424-8247/15/6/671/pdf?version=1653640259\)](#) 

**Investigation of the Role of the TRPA1 Ion Channel in Conveying the Effect of Dimethyl Trisulfide on Vascular and Histological Changes in Serum-Transfer Arthritis** ([/1424-8247/15/6/671](#))

Pharmaceuticals 2022, 15(6), 671; <https://doi.org/10.3390/ph15060671> (<https://doi.org/10.3390/ph15060671>) - 27 May 2022

Open Access Article

 [./\(1424-8247/15/6/670/pdf?version=1654140840\)](#) 

**QSAR, ADMET In Silico Pharmacokinetics, Molecular Docking and Molecular Dynamics Studies of Novel Bicyclo (Aryl Methyl) Benzamides as Potent GlyT1 Inhibitors for the Treatment of Schizophrenia** ([/1424-8247/15/6/670](#))

Pharmaceuticals 2022, 15(6), 670; <https://doi.org/10.3390/ph15060670> (<https://doi.org/10.3390/ph15060670>) - 27 May 2022


Open Access Article

 [./\(1424-8247/15/6/669/pdf?version=1654157844\)](#) 

**Novel High-Throughput Fluorescence-Based Assay for the Identification of Nematocidal Compounds That Target the Blood-Feeding Pathway** ([/1424-8247/15/6/669](#))

Pharmaceuticals 2022, 15(6), 669; <https://doi.org/10.3390/ph15060669> (<https://doi.org/10.3390/ph15060669>) - 27 May 2022

Open Access Article

 [./\(1424-8247/15/6/668/pdf?version=1653988967\)](#) 

**Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes** ([/1424-8247/15/6/668](#))

Pharmaceuticals 2022, 15(6), 668; <https://doi.org/10.3390/ph15060668> (<https://doi.org/10.3390/ph15060668>) - 26 May 2022

Open Access Review

 [./\(1424-8247/15/6/667/pdf?version=1653641046\)](#) 

**HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer** ([/1424-8247/15/6/667](#))

Pharmaceuticals 2022, 15(6), 667; <https://doi.org/10.3390/ph15060667> (<https://doi.org/10.3390/ph15060667>) - 26 May 2022



Open Access Article

 [./\(1424-8247/15/6/666/pdf?version=1653918577\)](#) 

**Synthesis, Physicochemical, Labeling and In Vivo Characterization of <sup>44</sup>Sc-Labeled DO3AM-NI as a Hypoxia-Sensitive PET Probe** ([/1424-8247/15/6/666](#))

Pharmaceuticals 2022, 15(6), 666; <https://doi.org/10.3390/ph15060666> (<https://doi.org/10.3390/ph15060666>) - 26 May 2022

Open Access Review

 [./\(1424-8247/15/6/665/pdf?version=1653559458\)](#) 

**Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors** ([/1424-8247/15/6/665](#))

Pharmaceuticals 2022, 15(6), 665; <https://doi.org/10.3390/ph15060665> (<https://doi.org/10.3390/ph15060665>) - 26 May 2022



Open Access Article

 [./\(1424-8247/15/6/664/pdf?version=1654757885\)](#) 

**Dihydroconiferyl Ferulate Isolated from *Dendropanax morbiferus* H.Lév. Suppresses Stemness of Breast Cancer Cells via Nuclear EGFR/c-Myc Signaling** ([/1424-8247/15/6/664](#))

Pharmaceuticals 2022, 15(6), 664; <https://doi.org/10.3390/ph15060664> (<https://doi.org/10.3390/ph15060664>) - 26 May 2022

Open Access Article

 [./\(1424-8247/15/6/663/pdf?version=1653551159\)](#) 

**Chemical Profiling of Kaliziri Injection and Quantification of Six Caffeoyl Quinic Acids in Beagle Plasma by LC-MS/MS** ([/1424-8247/15/6/663](#))

Pharmaceuticals 2022, 15(6), 663; <https://doi.org/10.3390/ph15060663> (<https://doi.org/10.3390/ph15060663>) - 25 May 2022

Open Access Article

 [./\(1424-8247/15/6/662/pdf?version=1655342849\)](#) 

**Surfactant-Free Chitosan/Cellulose Acetate Phthalate Nanoparticles: An Attempt to Solve the Needs of Captopril Administration in Paediatrics** ([/1424-8247/15/6/662](#))

Pharmaceuticals 2022, 15(6), 662; <https://doi.org/10.3390/ph15060662> (<https://doi.org/10.3390/ph15060662>) - 25 May 2022

Open Access Article

 [./\(1424-8247/15/6/661/pdf?version=1655352870\)](#) 

**Evaluation of Toxic Properties of New Glycopeptide Flavancin on Rats (1424-8247/15/6/661)**

MDPI  
Pharmaceuticals 2022, 15(6), 661; <https://doi.org/10.3390/ph15060661> (<https://doi.org/10.3390/ph15060661>) - 25 May 2022




Open Access Article

  [.\(1424-8247/15/6/660/pdf?version=1655543903\)](#) 

**Inflammatory Biomarkers of Traumatic Brain Injury (1424-8247/15/6/660)**

Pharmaceuticals 2022, 15(6), 660; <https://doi.org/10.3390/ph15060660> (<https://doi.org/10.3390/ph15060660>) - 25 May 2022



Open Access Article

  [.\(1424-8247/15/6/659/pdf?version=1653560570\)](#) 

**Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors (1424-8247/15/6/659)**

Pharmaceuticals 2022, 15(6), 659; <https://doi.org/10.3390/ph15060659> (<https://doi.org/10.3390/ph15060659>) - 25 May 2022



Open Access Review

  [.\(1424-8247/15/6/658/pdf?version=1653554342\)](#)

**A Review of the Phytochemistry and Pharmacological Properties of the Genus Arrabidaea (1424-8247/15/6/658)**

Pharmaceuticals 2022, 15(6), 658; <https://doi.org/10.3390/ph15060658> (<https://doi.org/10.3390/ph15060658>) - 25 May 2022



Open Access Article

  [.\(1424-8247/15/6/657/pdf?version=1653899038\)](#)

**Formulation and Characterization of Metformin-Loaded Ethosomes for Topical Application to Experimentally Induced Skin Cancer in Mice (1424-8247/15/6/657)**

Pharmaceuticals 2022, 15(6), 657; <https://doi.org/10.3390/ph15060657> (<https://doi.org/10.3390/ph15060657>) - 25 May 2022

Open Access Review

  [.\(1424-8247/15/6/656/pdf?version=1653537457\)](#)

**Cardiac <sup>123</sup>I-mIBG Imaging in Heart Failure (1424-8247/15/6/656)**

Pharmaceuticals 2022, 15(6), 656; <https://doi.org/10.3390/ph15060656> (<https://doi.org/10.3390/ph15060656>) - 25 May 2022

Open Access Review

  [.\(1424-8247/15/6/655/pdf?version=1653470872\)](#)

**Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy (1424-8247/15/6/655)**

Pharmaceuticals 2022, 15(6), 655; <https://doi.org/10.3390/ph15060655> (<https://doi.org/10.3390/ph15060655>) - 25 May 2022



Open Access Article

  [.\(1424-8247/15/6/654/pdf?version=1654529883\)](#) 

**Network Pharmacology and Bioinformatics Approach Reveals the Multi-Target Pharmacological Mechanism of *Fumaria indica* in the Treatment of Liver Cancer (1424-8247/15/6/654)**

Pharmaceuticals 2022, 15(6), 654; <https://doi.org/10.3390/ph15060654> (<https://doi.org/10.3390/ph15060654>) - 25 May 2022



Open Access Review

  [.\(1424-8247/15/6/653/pdf?version=1653469903\)](#)

**Technologies for Solubility, Dissolution and Permeation Enhancement of Natural Compounds (1424-8247/15/6/653)**

Pharmaceuticals 2022, 15(6), 653; <https://doi.org/10.3390/ph15060653> (<https://doi.org/10.3390/ph15060653>) - 25 May 2022


Open Access Article

  [.\(1424-8247/15/6/652/pdf?version=1653899773\)](#)

**Determination of the Dissolution/Permeation and Apparent Solubility for Microencapsulated Emamectin Benzoate Using In Vitro and Ex Vivo *Salmo salar* Intestine Membranes (1424-8247/15/6/652)**

Pharmaceuticals 2022, 15(6), 652; <https://doi.org/10.3390/ph15060652> (<https://doi.org/10.3390/ph15060652>) - 25 May 2022



Open Access Article

  [.\(1424-8247/15/6/651/pdf?version=1653532509\)](#) 

**Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes (1424-8247/15/6/651)**

Pharmaceuticals 2022, 15(6), 651; <https://doi.org/10.3390/ph15060651> (<https://doi.org/10.3390/ph15060651>) - 24 May 2022



Open Access Article

  [.\(1424-8247/15/6/650/pdf?version=1653385597\)](#) 

**Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma (1424-8247/15/6/650)**

Pharmaceuticals 2022, 15(6), 650; <https://doi.org/10.3390/ph15060650> (<https://doi.org/10.3390/ph15060650>) - 24 May 2022



Open Access Review

  [.\(1424-8247/15/6/649/pdf?version=1653379114\)](#)

**Nitrative Stress and Auditory Dysfunction (1424-8247/15/6/649)**

Pharmaceuticals 2022, 15(6), 649; <https://doi.org/10.3390/ph15060649> (<https://doi.org/10.3390/ph15060649>) - 24 May 2022



Open Access Review

  [.\(1424-8247/15/6/648/pdf?version=1653378597\)](#)

**Novel Effects of Statins on Cancer via Autophagy (1424-8247/15/6/648)**

Pharmaceuticals 2022, 15(6), 648; <https://doi.org/10.3390/ph15060648> (<https://doi.org/10.3390/ph15060648>) - 24 May 2022

Open Access Editorial

  [.\(1424-8247/15/6/647/pdf?version=1653380350\)](#)

**Special Issue "GPCRs: Ligands and beyond 2022" (1424-8247/15/6/647)**

Pharmaceuticals 2022, 15(6), 647; <https://doi.org/10.3390/ph15060647> (<https://doi.org/10.3390/ph15060647>) - 24 May 2022

**Show export options** 

Displaying articles 1-121

Previous Issue

**Volume 15, May (1424-8247/15/5)**

Next Issue

**Volume 15, July (1424-8247/15/7)**





Further Information

[\(toggle desktop layout cookie\)](#)

[Article Processing Charges \(/apc\)](#)

[Pay an Invoice \(/about/payment\)](#)

[Open Access Policy \(/openaccess\)](#)

[Contact MDPI \(/about/contact\)](#)

[Jobs at MDPI \(https://careers.mdpi.com\)](https://careers.mdpi.com)

Guidelines

[For Authors \(/authors\)](#)

[For Reviewers \(/reviewers\)](#)

[For Editors \(/editors\)](#)

[For Librarians \(/librarians\)](#)

[For Publishers \(/publishing\\_services\)](#)

[For Societies \(/societies\)](#)

[For Conference Organizers \(/conference\\_organizers\)](#)

MDPI Initiatives

[Sciforum \(https://sciforum.net\)](https://sciforum.net)

[MDPI Books \(https://www.mdpi.com/books\)](https://www.mdpi.com/books)

[Preprints.org \(https://www.preprints.org\)](https://www.preprints.org)

[Scilit \(https://www.scilit.net\)](https://www.scilit.net)

[SciProfiles \(https://sciprofiles.com\)](https://sciprofiles.com)

[Encyclopedia \(https://encyclopedia.pub\)](https://encyclopedia.pub)

[JAMS \(https://jams.pub\)](https://jams.pub)

[Proceedings Series \(/about/proceedings\)](#)

Follow MDPI

[LinkedIn \(https://www.linkedin.com/company/mdpi\)](https://www.linkedin.com/company/mdpi)

[Facebook \(https://www.facebook.com/MDPIOpenAccessPublishing\)](https://www.facebook.com/MDPIOpenAccessPublishing)

[Twitter \(https://twitter.com/MDPIOpenAccess\)](https://twitter.com/MDPIOpenAccess)

Subscribe to receive issue release notifications and newsletters from MDPI journals

## Article

# Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic-Acid-Metabolizing Genes in the Mouse Lungs

Fatima Khirfan <sup>1</sup>, Yazun Jarrar <sup>1,\*</sup>, Tariq Al-Qirim <sup>1</sup>, Khang Wen Goh <sup>2</sup>, Qais Jarrar <sup>3</sup>, Chrismawan Ardianto <sup>4,\*</sup>, Mohammad Awad <sup>1</sup>, Hamzeh J. Al-Ameer <sup>5</sup>, Wajdy Al-Awaida <sup>5</sup>, Said Moshawih <sup>6</sup> and Long Chiau Ming <sup>4,6,\*</sup>

- <sup>1</sup> Department of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11731, Jordan; fatimakhirfan@yahoo.com (F.K.); tariq.qirim@zuj.edu.jo (T.A.-Q.); mohammadkawad96@gmail.com (M.A.)
- <sup>2</sup> Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia; khangwen.goh@newinti.edu.my
- <sup>3</sup> Department of Applied Pharmaceutical Sciences, Faculty of Pharmacy, Al-Isra University, Amman 11622, Jordan; qais.jarrar@iu.edu.jo
- <sup>4</sup> Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia
- <sup>5</sup> Department of Biology and Biotechnology, American University of Madaba, Madaba 17110, Jordan; hamzeh\_uj@yahoo.com (H.J.A.-A.); w.alawaida@aum.edu.jo (W.A.-A.)
- <sup>6</sup> PAP Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei Darussalam; saeedmomo@hotmail.com
- \* Correspondence: yazun.jarrar@zuj.edu.jo (Y.J.); chrismawan-a@ff.unair.ac.id (C.A.); long.ming@ubd.edu.bn (L.C.M.)



**Citation:** Khirfan, F.; Jarrar, Y.; Al-Qirim, T.; Goh, K.W.; Jarrar, Q.; Ardianto, C.; Awad, M.; Al-Ameer, H.J.; Al-Awaida, W.; Moshawih, S.; et al. Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic-Acid-Metabolizing Genes in the Mouse Lungs. *Pharmaceuticals* **2022**, *15*, 696. <https://doi.org/10.3390/ph15060696>

Academic Editors: Jean Jacques Vanden Eynde and Annie Mayence

Received: 9 April 2022

Accepted: 28 May 2022

Published: 1 June 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Paracetamol and nonsteroidal anti-inflammatory drugs are widely used in the management of respiratory viral infections. This study aimed to determine the effects of the most commonly used analgesics (paracetamol, ibuprofen, and diclofenac) on the mRNA expression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry and arachidonic-acid-metabolizing genes in mouse lungs. A total of twenty eight Balb/c mice were divided into four groups and treated separately with vehicle, paracetamol, ibuprofen, and diclofenac in clinically equivalent doses for 14 days. Then, the expressions of SARS-CoV-2 entry, *ACE2*, *TMPRSS2*, and *Ctstl* genes, in addition to the arachidonic-acid-metabolizing *cyp450*, *cox*, and *alox* genes, were analyzed using real-time PCR. Paracetamol increased the expressions of *TMPRSS2* and *Ctstl* genes by 8.5 and 5.6 folds, respectively, while ibuprofen and diclofenac significantly decreased the expression of the *ACE2* gene by more than 2.5 folds. In addition, all tested drugs downregulated ( $p < 0.05$ ) *cox2* gene expression, and paracetamol reduced the mRNA levels of *cyp4a12* and *2j5*. These molecular alterations in diclofenac and ibuprofen were associated with pathohistological alterations, where both analgesics induced the infiltration of inflammatory cells and airway wall thickening. It is concluded that analgesics such as paracetamol, ibuprofen, and diclofenac alter the expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes in mouse lungs.

**Keywords:** COVID-19; lung disease; chronic respiratory disease; acute respiratory distress syndrome; gene expression

## 1. Introduction

COVID-19 infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This viral infection became a global endemic disease in 2019. The SARS-CoV-2 virus infects mainly the respiratory system and enters epithelial cells through interaction between the viral spike and specific proteins on the host cells [1,2]. SARS-CoV-2 attaches to the angiotensin-converting enzyme type 2 (ACE2) receptor at the top of host cells [3,4]. This mechanism cannot be completed without a human cathepsin L (CTSL) protease that cuts the S-glycoprotein at exact locations to let the SARS-CoV-2 attach to the host cell

surface [5]. In addition, the human transmembrane protease serine 2 (TMPRSS2) stimulates the entrance of the SARS-CoV-2 virus into the epithelial cells [5,6]. TMPRSS2 works by splitting the virus, leading to the detaching of the spike piece, and helps in the spread of the SARS-CoV-2 virus [7]. It was suggested that factors that alter the expression of SARS-CoV-2 entry protein can affect the risk and severity of COVID-19 infection.

The major symptoms of the COVID-19 infection are fever and malaise [8,9]. Therefore, analgesics and antipyretics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol, are used to manage fever [10]. Furthermore, these analgesics can alleviate some COVID-19 infection symptoms, such as body pain [11]. NSAIDs exert their interaction through the inhibition of arachidonic acid metabolism to prostaglandins. NSAIDs can affect arachidonic-acid-metabolizing cytochrome P450s (cyp450s), cyclooxygenases (coxs), and lipooxygenases (aloxs) in different organs, including the liver, kidneys, and heart [12,13].


Clinical observations showed that when some patients with COVID-19 infection and no other diseases were given NSAIDs, their symptoms worsened. Additionally, another clinical study reported COVID-19 exacerbation after taking NSAIDs [14].

There is a lack of in vivo studies regarding the influence of NSAIDs and paracetamol on the expression of SARS-CoV-2 entry genes. We hypothesized that NSAIDs induced the expression of pulmonary SARS-CoV-2 entry genes. Therefore, we aimed to determine the effects of paracetamol and the most commonly used NSAIDs, ibuprofen and diclofenac, on the expression of the SARS-CoV-2 entry gene in the lungs of treated mice. Furthermore, disturbances in the expressions of mouse arachidonic-acid-metabolizing *cyp450*, *cox*, and *alox* genes caused by the analgesics in the lungs were determined.

## 2. Results

### 2.1. Physical Observation


Figure 1 shows the change in mice weight of all tested groups. We did not find a significant change ( $p > 0.05$ ) in their weight on the seventh or the last day of drug administration.



**Figure 1.** The changes in total body weight of the experimental mice. There was no significant change ( $p > 0.05$ , two-way ANOVA) in the total body weight after 14 days of analgesic treatment.

### 2.2. Histological Analysis


Figure 2 presents the histological sections of the mouse lungs after administration of paracetamol, ibuprofen, and diclofenac for 14 consecutive days. We found that 14 injections of ibuprofen (Figure 2B), and diclofenac (Figure 2C), but not paracetamol (Figure 2D), induced the inflammatory cell infiltration and airway wall thickening in the lungs of the treated mice.



**Figure 2.** Histopathologic lungs analysis of animals after treatment. (A) Control lung section shows the normal structure of the bronchiole and adjacent alveoli. (B) Ibuprofen-treated mice representative lung section showing normal lung histology. (C) Diclofenac-treated mice lung tissue section showing normal bronchus and adjacent alveoli. (D) Paracetamol-treated mice lung tissue showing normal bronchial and alveolar tissues. Thick arrows indicate thickening in the alveolar wall; thin arrows indicate inflammatory cell infiltration. Tissue sections were stained with hematoxylin and eosin (scale bar 100  $\mu\text{m}$ ) and photographed at 40 $\times$  magnification.


### 2.3. mRNA Levels of SARS-CoV-2 Entry Gene

We found in this study that *Ctst1* was the most highly expressed SARS-CoV-2 entry gene in the mouse lungs. *Ctst1* was expressed 2.7 times more than *ACE2* ( $p = 0.01$ ), which was 15 times higher than *TMPRSS2* gene ( $p < 0.0001$ ). The relative expression of SARS-CoV-2 entry genes in the mouse lungs is illustrated in Figure 3.



**Figure 3.** Relative mRNA expression of SARS-CoV-2 entry genes in the mouse lungs. \* indicates a statistical alteration ( $p < 0.05$ , one-way ANOVA test).


The mRNA expression of the *ACE2* gene was significantly downregulated in the mouse lungs after administration of ibuprofen ( $p = 0.02$ ) and diclofenac ( $p = 0.02$ ) by 2.6 and 2.7 folds, respectively (Figure 4A). The expression of the mouse *TMPRSS2* gene was significantly decreased ( $p = 0.008$ ) after paracetamol treatment by 8.54 folds. Although the NSAIDs ibuprofen and diclofenac upregulated the expression of *TMPRSS2* gene by 4 and 2.6 folds, respectively (Figure 4B), this upregulation of *TMPRSS2* by NSAIDs failed to reach statistical significance ( $p = 0.10$ – $0.27$ ). In addition, paracetamol only downregulated the expression of the *Ctstl* gene by 5.59-fold ( $p = 0.006$ ) (Figure 4C).



**Figure 4.** Expressions of SARS-CoV-2 entry genes *ACE2* (A), *TMPRSS2* (B), and *Ctstl* (C) in the lungs of NSAID- and paracetamol-treated mice. The mRNA expression of the targeted genes was quantified relative to *Actin* expression. Fold change indicates the ratio of mean expression of the NSAID- and paracetamol-treated to the control value. Negative values indicate a reduction in fold change. \* indicates a statistical difference ( $p < 0.05$ , one-way ANOVA test) in comparison with the control group.

#### 2.4. mRNA Levels of Arachidonic-Acid-Metabolizing *cox* Gene


We found that all tested analgesics did not significantly affect ( $p = 0.7$ – $0.9$ ) the expression of the lung *cox1* gene (Figure 5A). However, all tested analgesics caused a significant ( $p = 0.01$ – $0.04$ ) downregulation of the mouse lung *cox2* after 14 days of administration (Figure 5B). The strongest effect on the *cox2* gene expression was observed for diclofenac, which downregulated the mRNA expression of the *cox2* gene by 2.7 folds ( $p = 0.01$ ).



**Figure 5.** Expression of *cox1* (A) and *cox2* (B) genes in the lungs of NSAID- and paracetamol-treated mice. The target expression was quantified relative to the expression of *Actin* gene. Fold change is the ratio of mean expression of the NSAID- and paracetamol-treated to the control value. Negative values indicate a reduction in fold change. \* indicates a statistical difference ( $p < 0.05$ , one-way ANOVA test) in comparison with the control group, while # indicates a statistical difference in comparison of diclofenac with other analgesics.

### 2.5. mRNA Levels of Arachidonic-Acid-Metabolizing *alox* Gene

We found that only paracetamol had a significant ( $p = 0.009$ ) effect on the expression of *alox12*, as shown in Figure 6A,B. Paracetamol downregulated the expression of the *alox12* gene by 3.59 folds (Figure 6A).




**Figure 6.** Expression of *alox12* (A) and 15 (B) genes in the lungs of NSAID- and paracetamol-treated mice. The target expression was quantified relative to the expression of *actin* gene. Fold change is the ratio of mean expression of the NSAID- and paracetamol-treated to the control value. Negative values indicate a reduction in fold change; \* indicates a statistical difference ( $p < 0.05$ , one-way ANOVA test) in comparison with the control group.

### 2.6. mRNA Levels of Arachidonic-Acid-Metabolizing *cyp450* Gene

Figure 7A–C presents the influences of paracetamol, ibuprofen, and diclofenac on the expression of the arachidonic-acid-metabolizing *cyp450* genes in the lungs of the treated mice. Paracetamol significantly ( $p = 0.03$ ) downregulated the *cyp4a12* gene by three folds

(Figure 7A). Additionally, paracetamol significantly reduced ( $p = 0.01$ ) the expression of the mouse *cyp2j5* gene in the lung by 4.2 folds (Figure 7B).



**Figure 7.** Expressions of *cyp4a12* (A), *cyp2j5* (B), and *cyp2c29* (C) genes in the lungs of NSAID- and paracetamol-treated mice. The target expression was quantified relative to the expression of the actin gene. Fold change is the ratio of mean expression of the NSAID- and paracetamol-treated to the control value; negative values indicate a reduction in fold change; \* indicates a statistical difference ( $p < 0.05$ , one-way ANOVA test) in comparison with the control group.

Regarding *cyp2c29* gene expression, only diclofenac significantly induced ( $p = 0.009$ ) its mRNA expression, by 4.8 folds (Figure 7C). Although the other NSAID, ibuprofen, showed a slight increase in the mRNA levels of the *cyp2c29* gene (2.3 folds), this induction failed to reach statistical significance ( $p = 0.27$ ). Lastly, we found that the *cyp3a11* gene was not expressed in the mouse lung when tested using a RT-PCR assay.

### 3. Discussion

Analgesics are widely used in the management of fatigue and fever, which are the symptoms of viral infections, including COVID-19. However, there are controversial reports regarding the use of NSAIDs in the management of COVID-19 symptoms, and it

is recommended to replace NSAIDs with paracetamol [15,16]. In this study, we showed that NSAIDs and paracetamol significantly affected the mRNA expression of the SARS-CoV-2 entry gene, and caused an imbalance in the mRNA expression of arachidonic-acid-metabolizing genes. The pattern of paracetamol's effect on the expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes was different than that of ibuprofen and diclofenac. These differences between paracetamol and NSAIDs, regarding their influence on the mRNA expression of SARS-CoV-2 entry genes, may explain, at least partly, the differences between paracetamol and NSAIDs in the clinical management of COVID-19 symptoms. Further clinical studies are needed to confirm the findings of this study.

Toxicological studies used body weight and pathohistological examinations as markers of drug-induced toxicity on the animals and organs [16]. In this study, we found that 14 days of treatment with all drugs did not change the body weight. However, ibuprofen and diclofenac caused toxicological changes, as indicated by the results of the histological examination of the mouse lungs, where both NSAIDs caused infiltration of inflammatory cells and increased the thickness of the wall of the bronchioles. It was reported that NSAIDs have the capacity to induce oxidative stress in the cells [16]. Accordingly, the molecular alterations in the mRNA expression of arachidonic-acid-metabolizing genes, *Ctstl*, *TMPRSS2*, and *ACE2*, were associated with the toxicological effects of NSAIDs on the mouse lung *TMPRSS2ACE2*. Our results showed that paracetamol did not induce pathohistological alterations in the mouse lungs after 14 days of administration. We concluded that paracetamol is relatively safer than NSAIDs on the lungs, and that these findings support the use of paracetamol, rather than NSAIDs, for patients suffering from pulmonary diseases.

Our findings indicated that *Ctstl* is the most highly expressed SARS-CoV-2 entry gene in the mouse lungs. This indicated that the *Ctstl* protein can be considered as an important target for the prevention of SARS-CoV-2 entry into epithelial lung cells. It was reported that the inhibition of *Ctstl* prevents severe respiratory infections caused by viral infections [17].

Although the *TMPRSS2* gene is expressed in lower amounts than *ACE2* and *Ctstl*, inhibitors of *TMPRSS2* protein, such as ambroxol, can clinically reduce the severity of SARS-CoV infections [18]. In this study, we found that paracetamol downregulated the mRNA expression of the *Ctstl* and *TMPRSS2* genes. Our findings are in line with those of Sharif-Askari et al.: paracetamol can reduce the expression of the human *TMPRSS2* gene using in silico methods [19]. This finding indicated that paracetamol has a favorable effect over ibuprofen and diclofenac in decreasing the entry of SARS-CoV-2 into the epithelial cells. Interestingly, it was found that paracetamol has an antiviral effect [20], and that decreasing *TMPRSS2* and *Ctstl* expressions might be a mechanism of paracetamol against the entry of viruses into the host cells.

There is a controversial report regarding the correlation between human *ACE2* expression and the severity of COVID-19 infection. It was suggested that patients with increased susceptibility to COVID-19 complications have reduced levels of human *ACE2* [18]. The current study reported that NSAIDs, but not paracetamol, decreased the mRNA expression of the mouse *ACE2* gene in the lungs. In agreement with the findings reported by Sharif-Askari et al., ibuprofen can reduce the expression of the human *ACE2* gene using in silico methods [21]. This finding may explain, at least in part, the harmful effects of NSAIDs on COVID-19 patients.

In this study, we found that all tested analgesics decreased the expression of the mouse *cox2* gene, which plays a major role in inflammation [22]. Therefore, this finding may explain the anti-inflammatory effect of all tested analgesics, including paracetamol [23]. Furthermore, we found that diclofenac decreased the expression of the *cox2* gene more than ibuprofen and paracetamol. Interestingly, diclofenac is considered a stronger analgesic than ibuprofen and paracetamol [24,25].

Alox12 causes bronchoconstriction by producing leukotrienes [26,27]. Some bronchodilator drugs target the formation of leukotrienes, and hence can be used in the treatment of asthma and chronic obstructive pulmonary diseases [28]. It was reported that



NSAIDs are contraindicated in patients with asthma disease because that NSAIDs increase the synthesis of leukotrienes [29]. On the other hand, paracetamol is considered safer than NSAIDs as an analgesic and antipyretic for asthmatic patients [30]. We found that paracetamol decreased the mRNA expression of the mouse *alox12* gene. Therefore, we postulated that paracetamol can decrease the synthesis of leukotrienes through the downregulation of the expression of the *alox12* gene, which may explain the safety of paracetamol use among COVID-19 patients [31].

20-Hydroxyecostarionic acid (20-HETE) is synthesized by mouse *cyp4a12*. It was noticed that 20-HETE is overexpressed in hypoxia and vasoconstrictive pulmonary diseases [32,33]. Arachidonic acid is metabolized by mouse *cyp2j5* and *cyp2c19* to epoxyeicosatrienoic acids (EETs), which cause pulmonary vasoconstriction and hypoxia [33]. Paracetamol, but not NSAIDs, significantly downregulated the expression of *cyp4a12* and *cyp2j5* genes in the mouse lungs. On the other hand, we found that the *cyp2c29* gene expression was induced by the administration of diclofenac. Collectively, paracetamol decreased the mRNA expression of arachidonic-acid-metabolizing *cyp450s*.

In addition to arachidonic acid metabolism, *cyp2c29* is a phase I drug-metabolizing enzyme, which metabolizes many drugs, including warfarin [12]. Induction of the pulmonary *cyp2c29* enzyme by diclofenac may result in an increased drug metabolism in the lung. It was reported that diclofenac decreased the expression of the hepatic *cyp2c29* gene, which was associated with hepatotoxicological alterations in the liver [34]. This indicated that diclofenac has a tissue-dependent effect on the mRNA expression of the *cyp2c29* gene [34].

This study, for the first time, revealed that analgesics such as paracetamol, ibuprofen, and diclofenac induced alterations in the expressions of the ACE2 receptor, *Ctstl*, *TMPRSS2*, and arachidonic-acid-metabolizing genes in mouse lungs. However, this study also had some limitations. For example, the *in vivo* model employed Balb/c mice, which were not infected with SARS-CoV-2. However, our focus was the molecular effects of NSAIDs and paracetamol on the mouse ACE2, *TMPRSS2*, and *Ctstl* genes, which have nucleic and amino acid sequences that are close to those of humans. Another limitation is that we did not analyze the protein expression to confirm mRNA results. Furthermore, we did not analyze the levels and concentrations of arachidonic acid metabolites, which can indicate the influence of analgesics on the production of arachidonic acid metabolites in the lungs. To verify our findings, we need more *in vivo* experiments on humanized ACE2 and *TMPRSS2* mice. Additionally, further clinical studies are needed to confirm the findings of this study.

## 4. Material and Methods

### 4.1. Chemicals

Diclofenac sodium, ibuprofen, paracetamol, isopropyl alcohol, PEG400, and 75% alcohol were obtained from Sigma-Aldrich (St. Louis, MO, USA). Diclofenac sodium salt was solubilized in PEG400. TRIzol solution and a cDNA synthesis kit were purchased from ZYMO RESEARCH (Irvine, CA, USA). TB Green<sup>®</sup> Fast qPCR Mix was purchased from Takara Bio (Kusatsu, Japan). The oligonucleotides, for PCR reaction, were bought from Integrated DNA technologies (Coralville, IA, USA).

### 4.2. Experimental Animals

Twenty eight male Balb/c mice (*Mus musculus*) of the same age and weight were collected from the animal house of Jordan's Al-Zaytoonah University (Amman, Jordan). The mice were handled according to the Canadian Council on Animal Care's guidelines [35], and the study methodology was approved by Jordan's Al-Zaytoonah University's ethical committee with a reference number of 04/07/2020-2021. The mice were kept at a temperature of  $23 \pm 1$  °C with a 12 h light/12 h dark cycle. All mice were fed *ad libitum* with standard laboratory animal diet pellets.

#### 4.3. Experimental Protocol

After a 7-day stabilization period, the twenty eight mice were divided into four groups with seven each, as follows:

- (1) Control group: the mice received a once-daily intraperitoneal dose of 50% polyethylene glycol 400, the vehicle used for the solubilization of analgesic drugs.
- (2) Paracetamol group: the mice were administered a once-daily intraperitoneal injection of 50 mg/kg paracetamol.
- (3) Ibuprofen group: the mice were administered a once-daily intraperitoneal injection of 19.68 mg/kg ibuprofen.
- (4) Diclofenac group: the mice were treated with a once-daily intraperitoneal injection of 10 mg/kg diclofenac.

The drugs were administered to the animals for a continuous 14 days. The used doses of NSAIDs corresponded to the daily dose for humans, which depend on the surface area of the animal body [12]. This period of analgesic treatment mimicked the period of disease symptoms that were used in humans and found to be able to alter the expression of arachidonic-acid-metabolizing enzyme genes [12,36]. The mice were euthanized by cervical dislocation, as suggested by the Canadian Council on Animal Care [35].

#### 4.4. Physical Observation

Throughout the investigation, the mice's weights were measured three times. The first weight measurement was taken on the first day of drug administration, the second was taken one week later, and the final was taken on the last day of drug administration.

#### 4.5. Histological Analysis

The histological investigation was carried out according to the previously described protocol [12]. After the mice were sacrificed, the lung samples were dissected and cleaned with 0.9% normal saline before being fixed in 10% formalin for more than one day. The samples were next dehydrated by putting them through a graded series of alcohol, followed by xylene. The lung tissues were then embedded in paraffin wax. Hematoxylin and eosin were used to stain the obtained lung sections. Lastly, a Leica® (Wetzlar, Germany) microscope attached to a digital camera was used to photograph the prepared sections.

#### 4.6. RNA Extraction and cDNA Synthesis

After mouse sacrifice, about 200 mg of lung was isolated from each mouse. Then, triazol, isopropyl alcohol, and 75% alcohol were used to extract the pulmonary RNA, according to the manufacturer's instructions. Next, a cDNA Synthesis Kit® was used to convert the extracted mRNA to cDNA. Briefly, 1 mg of RNA was added to a reaction mixture containing 100 pmol oligo deoxythymine, 2.5 mM dNTP, 0.1 M DTT, 1 × reverse transcriptase buffer, and 100 units of Moloney Murine Leukemia Virus reverse transcriptase, and incubated for 60 min at 37 °C.

#### 4.7. Gene Expression Analysis

The expressions of mouse *ACE2*, *Ctstl*, *TMPRSS2*, *cox1*, *cox2*, *lox12*, *lox15*, *cyp4a12*, *cyp2j5*, *cyp2c29*, and *cyp1a1* genes were examined in this research. Table 1 shows the oligonucleotides sequence, amplicon size, and annealing temperature for each amplified gene. The expressions of these targeted genes were analyzed using quantitative real-time polymerase chain reaction (qRT-PCR), as prescribed previously [37]. Briefly, 10 ng of the synthesized cDNA was added to a reaction mixture containing qPCR Master Mix and 10 pmol of forward and reverse oligonucleotides. The PCR conditions used were as follows: denaturation at 95 °C for 3 min was followed by 40 cycles of denaturation at 95 °C for 10 s and annealing at 53–58 °C for 30 s (Table 1). The mouse *Actin* gene was used as a housekeeping gene in this study, and the expression of the genes was calculated using the  $\Delta\Delta\text{CT}$  method [38].

**Table 1.** The oligonucleotide sequence, amplicon size, and annealing temperature of mouse *ACE2*, *Cts1*, *TMPRSS2*, *cox1*, *cox2*, *lox12*, *lox15*, *cyp4a12*, *cyp2j5*, *cyp2c29*, and *cyp3a11* genes.

Gene Name	Forward	Reverse	Size	Annealing Temp. (°C)	Reported in
<i>ACE2</i>	ATTCACCCAACACTTGAGCC	TGTCCATCGAGTCATAAGGGT	213	55	This study
<i>Cts1</i>	AGGAAAATGGAGGTCTGGACT	GCAACAGAAATAGGCCCCAC	205	58	This study
<i>TMPRSS2</i>	CGTTCCCGTATACTCCAGGT	CGTTCCCGTATACTCCAGGT	221	58	This study
<i>cyp3a11</i>	ACAAACAAGCAGGGATGGAC	GGTAGAGGAGCACCAAGCTG	250	53	[38]
<i>cyp2c29</i>	AGGAGTTTCCCAACCCAGAG	TTCTTTGGGTGGACCAGAG	203	53	[38]
<i>cyp2j5</i>	GGGCCACTCCAGAAGTGT	CTGGCTGGAGAAAGGATGAG	235	53	[38]
<i>cyp4a12</i>	GCCTTCATCACAACCCAACCT	GGTATGGGGATTGGGACTCT	226	53	[39]
<i>alox12</i>	TGACGATGGAGACCGTGATG	GCT TTGGTCTTGGGTCT GA	223	58	[39]
<i>alox15</i>	AAA GGC ACTCTGTTGAAGCG	CACCAAGTGTCCCCTCAG AAG	204	59	[38]
<i>cox2</i>	CCTCCATTGACCAGAGCAGA	GTGCTCGGCTTCCAGTATTG	247	58	[40]
<i>b-Actin</i>	CCCCTGAGGAGCACCGTGTG	ATGGCTGGGGTGTGAAGGT	106	53	[41]

#### 4.8. Statistical Analysis

The change in the mRNA expression of the examined genes following analgesics administration is expressed as a number of fold changes in comparison with the control group. The mRNA expression of the tested genes, in each group, was normally distributed according to the Kolmogorov–Smirnov test. The comparison between the control and other groups was carried out using a two-way (for the body weight) and one-way (for the gene expression) analysis of variance (ANOVA) test and Tukey's *HSD* post hoc test. The change in expression of the examined genes was considered significant when *p* was less than 0.05. Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) version 23 for Windows.

## 5. Conclusions

The most commonly used analgesics (ibuprofen, diclofenac, and paracetamol) had a significant effect on the mRNA expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes in the mouse lung. These findings can explain, at least in part, the favorable use of paracetamol over NSAIDs in the management of pulmonary inflammation caused by viral infections, including COVID-19.

**Author Contributions:** Conceptualization, Y.J.; data curation, Y.J., C.A. and K.W.G.; formal analysis, Y.J., T.A.-Q. and L.C.M.; funding acquisition, Y.J., L.C.M. and S.M.; investigation, F.K., Y.J., T.A.-Q., M.A. and W.A.-A.; methodology, F.K., Y.J., M.A., H.J.A.-A. and W.A.-A.; project administration, Y.J. and C.A.; resources, C.A., L.C.M.; supervision, Y.J.; validation, Q.J., L.C.M. and C.A.; visualization, T.A.-Q., Q.J. and S.M.; writing—original draft, F.K., Y.J., T.A.-Q. and W.A.-A.; writing—review and editing, Q.J., M.A., H.J.A.-A., C.A., L.C.M. and S.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was funded by Al-Zaytoonah University of Jordan with fund number 20/06/2021-2022.

**Institutional Review Board Statement:** The animal study protocol was approved by the Ethics Committee of Al-Zaytoonah University of Jordan, 11731 Amman, 5/2020).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data are available from the corresponding authors.

**Acknowledgments:** The authors would like to thank the Deanship of Scientific Research in Al-Zaytoonah University and Universiti Brunei Darussalam for funding this research and publication.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–733. [[CrossRef](#)]
2. Cui, J.; Li, F.; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. *Nat. Rev. Microbiol.* **2019**, *17*, 181–192. [[CrossRef](#)]
3. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* **2020**, *395*, 1054–1062. [[CrossRef](#)]
4. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **2003**, *426*, 450–454. [[CrossRef](#)]
5. Glowacka, I.; Bertram, S.; Müller, M.A.; Allen, P.; Soilleux, E.; Pfeifferle, S.; Steffen, I.; Tsegaye, T.S.; He, Y.; Gnirss, K. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J. Virol.* **2011**, *85*, 4122–4134. [[CrossRef](#)]
6. Matsuyama, S.; Nao, N.; Shirato, K.; Kawase, M.; Saito, S.; Takayama, I.; Nagata, N.; Sekizuka, T.; Katoh, H.; Kato, F. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 7001–7003. [[CrossRef](#)] [[PubMed](#)]
7. Hafeez, A.; Ahmad, S.; Siddiqui, S.A.; Ahmad, M.; Mishra, S. A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. *Eurasian J. Med. Oncol.* **2019**, *4*, 116–125.
8. Israfil, S.M.H.; Sarker, M.M.R.; Rashid, P.T.; Talukder, A.A.; Kawsar, K.A.; Khan, F.; Akhter, S.; Poh, C.L.; Mohamed, I.N.; Ming, L.C. Clinical Characteristics and Diagnostic Challenges of COVID-19: An Update From the Global Perspective. *Front. Public Health* **2020**, *8*, 567395. [[CrossRef](#)]
9. Ng, S.L.; Ong, Y.S.; Khaw, K.Y.; Teh, S.P.; Tan, C.S.; Ming, L.C.; Chan, K.G.; Lee, L.H.; Goh, B.H. Focused Review: Potential Rare and Atypical Symptoms as Indicator for Targeted COVID-19 Screening. *Medicina* **2021**, *57*, 189. [[CrossRef](#)] [[PubMed](#)]
10. Little, P. Non-steroidal anti-inflammatory drugs and COVID-19. *BMJ* **2020**, *368*, m1185. [[CrossRef](#)] [[PubMed](#)]
11. Srivastava, P.; Vyas, V.K.; Variya, B.; Patel, P.; Qureshi, G.; Ghate, M. Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives. *Bioorg. Chem.* **2016**, *67*, 130–138. [[CrossRef](#)] [[PubMed](#)]
12. Jarrar, Y.B.; Jarrar, Q.; Abu-Shalhoob, M. Effects of nonsteroidal anti-inflammatory drugs on the expression of arachidonic acid-metabolizing Cyp450 genes in mouse hearts, kidneys and livers. *Prostaglandins Other Lipid Mediat.* **2019**, *141*, 14–21. [[CrossRef](#)] [[PubMed](#)]
13. Day, M. COVID-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists. *BMJ* **2020**, *368*, m1086. [[CrossRef](#)] [[PubMed](#)]
14. Pergolizzi, J.V.; Varrassi, G.; Magnusson, P.; LeQuang, J.A.; Paladini, A.; Taylor, R.; Wollmuth, C.; Breve, F.; Christo, P. COVID-19 and NSAIDs: A Narrative Review of Knowns and Unknowns. *Pain Ther.* **2020**, *9*, 353–358. [[CrossRef](#)] [[PubMed](#)]
15. Smart, L.; Fawkes, N.; Goggin, P.; Pennick, G.; Rainsford, K.; Charlesworth, B.; Shah, N. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: A dichotomy of expectation and reality. *Inflammopharmacology* **2020**, *28*, 1141–1152. [[CrossRef](#)]
16. da Silva Oliveira, G.L.; Machado, K.C.; Machado, K.C.; Feitosa, C.M.; de Castro Almeida, F.R. Non-clinical toxicity of  $\beta$ -caryophyllene, a dietary cannabinoid: Absence of adverse effects in female Swiss mice. *Regul. Toxicol. Pharmacol.* **2018**, *92*, 338–346. [[CrossRef](#)]
17. Olaleye, O.A.; Kaur, M.; Onyenaka, C.C. Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. *bioRxiv* **2020**. [[CrossRef](#)]
18. Saheb Sharif-Askari, N.; Saheb Sharif-Askari, F.; Alabed, M.; Tayoun, A.A.; Loney, T.; Uddin, M.; Senok, A.; Al Heialy, S.; Hamoudi, R.; Kashour, T. Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue. *Clin. Transl. Sci.* **2020**, *13*, 1048–1054. [[CrossRef](#)]
19. Lauder, S.N.; Taylor, P.R.; Clark, S.R.; Evans, R.L.; Hindley, J.P.; Smart, K.; Leach, H.; Kidd, E.J.; Broadley, K.J.; Jones, S.A. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. *Thorax* **2011**, *66*, 368–374. [[CrossRef](#)]
20. Du, F.; Liu, B.; Zhang, S. COVID-19: The role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. *J. Thromb. Thrombolysis* **2020**, *51*, 313–329. [[CrossRef](#)]
21. Lucarini, L.; Durante, M.; Sgambellone, S.; Lanzi, C.; Bigagli, E.; Akgul, O.; Masini, E.; Supuran, C.T.; Carta, F. Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis. *Biomolecules* **2020**, *10*, 1307. [[CrossRef](#)] [[PubMed](#)]
22. Graham, G.G.; Scott, K.F. Mechanisms of action of paracetamol and related analgesics. *Inflammopharmacology* **2003**, *11*, 401–413. [[CrossRef](#)] [[PubMed](#)]
23. Thenarasu, V.; Gurunathan, D.; Selvarasu, K. Comparison of Efficacy of Diclofenac and Paracetamol as Preemptive Analgesic Agent. *Biomed. Pharmacol. J.* **2018**, *11*, 1699–1706. [[CrossRef](#)]
24. Gazal, G.; Al-Samadani, K.H. Comparison of paracetamol, ibuprofen, and diclofenac potassium for pain relief following dental extractions and deep cavity preparations. *Saudi Med. J.* **2017**, *38*, 284. [[CrossRef](#)]
25. Roumeliotis, A.K.; Roumeliotis, S.K.; Panagoutsos, S.A.; Tsetsos, F.; Georgitsi, M.; Manolopoulos, V.; Paschou, P.; Passadakis, P.S. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy. *Int. Urol. Nephrol.* **2018**, *50*, 321–329. [[CrossRef](#)] [[PubMed](#)]

26. Zheng, Z.; Li, Y.; Jin, G.; Huang, T.; Zou, M.; Duan, S. The biological role of arachidonic acid 12-lipoxygenase (ALOX12) in various human diseases. *Biomed. Pharmacother.* **2020**, *129*, 110354. [[CrossRef](#)] [[PubMed](#)]
27. Sirois, P. Leukotrienes: One step in our understanding of asthma. *Respir. Investig.* **2019**, *57*, 97–110. [[CrossRef](#)] [[PubMed](#)]
28. Lo, P.C.; Tsai, Y.T.; Lin, S.K.; Lai, J.N. Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: A nationwide population-based cohort study in Taiwan. *Medicine* **2016**, *95*, e5109. [[CrossRef](#)]
29. Thomsen, S.F.; Kyvik, K.O.; Skadhauge, L.; Steffensen, I.; Backer, V. Intake of paracetamol and risk of asthma in adults. *J. Asthma* **2008**, *45*, 675–676. [[CrossRef](#)]
30. Micallef, J.; Soeiro, T.; Annie-Pierre, J.B. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. *Therapies* **2020**, *75*, 355–362. [[CrossRef](#)]
31. Wang, J.; Lian, G.; Luo, L.; Wang, T.; Xu, C.; Wang, H.; Xie, L. Role of 20-hydroxyeicosatetraenoic acid in pulmonary hypertension and proliferation of pulmonary arterial smooth muscle cells. *Pulm. Pharmacol. Ther.* **2020**, *64*, 101948. [[CrossRef](#)]
32. Chen, L.; Joseph, G.; Zhang, F.F.; Nguyen, H.; Jiang, H.; Gotlinger, K.H.; Falck, J.R.; Yang, J.; Schwartzman, M.L.; Guo, A.M. 20-HETE contributes to ischemia-induced angiogenesis. *Vasc. Pharmacol.* **2016**, *83*, 57–65. [[CrossRef](#)]
33. Guo, Y.; Weller, P.; Farrell, E.; Cheung, P.; Fitch, B.; Clark, D.; Wu, S.-y.; Wang, J.; Liao, G.; Zhang, Z. In silico pharmacogenetics of warfarin metabolism. *Nat. Biotechnol.* **2006**, *24*, 531–536. [[CrossRef](#)]
34. Jarrar, Y.; Al-Doaiss, A.; Alfaifi, M.; Shati, A.; Al-Kahtani, M.; Jarrar, B. The influence of five metallic nanoparticles on the expression of major drug-metabolizing enzyme genes with correlation of inflammation in mouse livers. *Environ. Toxicol. Pharmacol.* **2020**, *80*, 103449. [[CrossRef](#)]
35. Canadian Council on Animal Care. CCAC Guidelines: Mice. 2019. Available online: <https://ccac.ca/en/standards/guidelines/types-of-animals.html> (accessed on 22 May 2022).
36. Centers for Disease Control and Prevention. *Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)*; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2020.
37. Hou, F.; Li, S.; Wang, J.; Kang, X.; Weng, Y.; Xing, G. Identification and validation of reference genes for quantitative real-time PCR studies in long yellow daylily, *Hemerocallis citrina* Borani. *PLoS ONE* **2017**, *12*, e0174933. [[CrossRef](#)]
38. Jarrar, Y.B.; Al-Essa, L.; Kilani, A.; Hasan, M.; Al-Qerem, W. Alterations in the gene expression of drug and arachidonic acid-metabolizing Cyp450 in the livers of controlled and uncontrolled insulin-dependent diabetic mice. *Diabetes Metab. Syndr. Obes. Targets Ther.* **2018**, *11*, 483. [[CrossRef](#)]
39. Bickford, J.S.; Mueller, C.; Newsom, K.J.; Barilovits, S.J.; Beachy, D.E.; Herlihy, J.D.; Keeler, B.; Flotte, T.R.; Nick, H.S. Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency. *J. Cyst. Fibros.* **2013**, *12*, 258–265. [[CrossRef](#)]
40. Veres-Székely, A.; Pap, D.; Sziksz, E.; Jávorszky, E.; Rokonay, R.; Lippai, R.; Tory, K.; Fekete, A.; Tulassay, T.; Szabó, A.J. Selective measurement of  $\alpha$  smooth muscle actin: Why  $\beta$ -actin can not be used as a housekeeping gene when tissue fibrosis occurs. *BMC Mol. Biol.* **2017**, *18*, 12. [[CrossRef](#)]
41. Yousefifard, M.; Zali, A.; Zarghi, A.; Madani Neishaboori, A.; Hosseini, M.; Safari, S. Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence. *Int. J. Clin. Pract.* **2020**, *74*, e13557. [[CrossRef](#)]

NSAIDs are contraindicated in patients with asthma disease because that NSAIDs increase the synthesis of leukotrienes [29]. On the other hand, paracetamol is considered safer than NSAIDs as an analgesic and antipyretic for asthmatic patients [30]. We found that paracetamol decreased the mRNA expression of the mouse *alox12* gene. Therefore, we postulated that paracetamol can decrease the synthesis of leukotrienes through the downregulation of the expression of the *alox12* gene, which may explain the safety of paracetamol use among COVID-19 patients [31].

20-Hydroxyecostarionic acid (20-HETE) is synthesized by mouse *cyp4a12*. It was noticed that 20-HETE is overexpressed in hypoxia and vasoconstrictive pulmonary diseases [32,33]. Arachidonic acid is metabolized by mouse *cyp2j5* and *cyp2c19* to epoxyeicosatrienoic acids (EETs), which cause pulmonary vasoconstriction and hypoxia [33]. Paracetamol, but not NSAIDs, significantly downregulated the expression of *cyp4a12* and *cyp2j5* genes in the mouse lungs. On the other hand, we found that the *cyp2c29* gene expression was induced by the administration of diclofenac. Collectively, paracetamol decreased the mRNA expression of arachidonic-acid-metabolizing *cyp450s*.

In addition to arachidonic acid metabolism, *cyp2c29* is a phase I drug-metabolizing enzyme, which metabolizes many drugs, including warfarin [12]. Induction of the pulmonary *cyp2c29* enzyme by diclofenac may result in an increased drug metabolism in the lung. It was reported that diclofenac decreased the expression of the hepatic *cyp2c29* gene, which was associated with hepatotoxicological alterations in the liver [34]. This indicated that diclofenac has a tissue-dependent effect on the mRNA expression of the *cyp2c29* gene [34].

This study, for the first time, revealed that analgesics such as paracetamol, ibuprofen, and diclofenac induced alterations in the expressions of the ACE2 receptor, *Ctstl*, *TMPRSS2*, and arachidonic-acid-metabolizing genes in mouse lungs. However, this study also had some limitations. For example, the in vivo model employed Balb/c mice, which were not infected with SARS-CoV-2. However, our focus was the molecular effects of NSAIDs and paracetamol on the mouse ACE2, *TMPRSS2*, and *Ctstl* genes, which have nucleic and amino acid sequences that are close to those of humans. Another limitation is that we did not analyze the protein expression to confirm mRNA results. Furthermore, we did not analyze the levels and concentrations of arachidonic acid metabolites, which can indicate the influence of analgesics on the production of arachidonic acid metabolites in the lungs. To verify our findings, we need more in vivo experiments on humanized ACE2 and *TMPRSS2* mice. Additionally, further clinical studies are needed to confirm the findings of this study.

## 4. Material and Methods

### 4.1. Chemicals

Diclofenac sodium, ibuprofen, paracetamol, isopropyl alcohol, PEG400, and 75% alcohol were obtained from Sigma-Aldrich (St. Louis, MO, USA). Diclofenac sodium salt was solubilized in PEG400. TRIzol solution and a cDNA synthesis kit were purchased from ZYMO RESEARCH (Irvine, CA, USA). TB Green® Fast qPCR Mix was purchased from Takara Bio (Kusatsu, Japan). The oligonucleotides, for PCR reaction, were bought from Integrated DNA technologies (Coralville, IA, USA).

### 4.2. Experimental Animals

Twenty eight male Balb/c mice (*Mus musculus*) of the same age and weight were collected from the animal house of Jordan's Al-Zaytoonah University (Amman, Jordan). The mice were handled according to the Canadian Council on Animal Care's guidelines [35], and the study methodology was approved by Jordan's Al-Zaytoonah University's ethical committee with a reference number of 04/07/2020-2021. The mice were kept at a temperature of  $23 \pm 1$  °C with a 12 h light/12 h dark cycle. All mice were fed ad libitum with standard laboratory animal diet pellets.



## IDP Adalah Co-Owner IELTS

## Pharmaceuticals

### COUNTRY

Switzerland

Universities and research institutions in Switzerland

Media Ranking in Switzerland

### PUBLISHER

Multidisciplinary Digital Publishing Institute (MDPI)

### H-INDEX

69

### Regulatory Services

Medical Devices and Pharma can expedite your successful 510(k) submission

### SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology  
Molecular Medicine

Pharmacology, Toxicology and Pharmaceutics  
Drug Discovery  
Pharmaceutical Science

### PUBLICATION TYPE

Journals

### ISSN

14248247

### COVERAGE

2009-2021

### INFORMATION

[Homepage](#)

[How to publish in this journal](#)

Jean-Jacques.VANDENEYN  
DE@ex.umons.ac.be

### SCOPE

Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the length of a paper. The multidisciplinary journal welcomes manuscripts covering a wide range of aspects involved in drug discovery and development. The following topics are considered: Small molecules as drug candidates: drug discovery, drug design, medicinal chemistry, combinatorial chemistry, SAR, structure-property correlations, molecular modeling, pharmacophore, and bioinformatics; Biomolecules, natural products, phages, and cells as therapeutic tools: peptides, aptamers, glycans, antibodies, extracts, bacteriophages, and stem cells; Biological targets and biomarkers: enzymes, receptors, membranes, genes, ion channels, inhibitors, agonists, antagonists, neurons, binding affinity, biofilms, bacteria, viruses, parasites, and protein-protein interactions; Radiopharmaceutical sciences, radiochemistry, (hybrid-)imaging, and nuclear medicine: radiopharmaceuticals, radiotracers, fluorescent dye labeled tracers, contrast agents, PET/CT, PET/MRI RMI, SPECT/CT, and scintigraphy; Pharmacokinetics and pharmacodynamics: pharmaceutical analyses, drug effects, ADME, animal experimentation, and clinical trials; Pharmaceutical preparations and drug delivery: dosage form design, bioconjugates, prodrugs, formulation, metabolites, nanomaterials, nanomedicines, and drug targeting.

Join the conversation about this journal

### Game-Changing Technology

Precision Engineered Novel Disease Treatments | Verseon

Verseon is able to bring truly innovative treatments to life.

verseon.com

OPEN



1 **Current Medicinal Chemistry**

ARE

**76%**  
similarity

2 **Frontiers in Pharmacology**

CHE

**75%**  
similarity

3 **Current Drug Targets**

ARE

**74%**  
similarity

4 **International Journal of Molecular Sciences**

CHE

**70%**  
similarity

5 **Pharmacological Research**

USA

**69%**  
similarity


**Game-Changing Technology**

**Precision Engineered Novel Disease Treatments | Verseon**

Verseon is able to bring truly innovative treatments to life.

verseon.com

OPEN



Metrics based on Scopus® data as of April 2022

A **Ahmad Khalaf** 10 months ago  
Thanks;  
Happy to join with you  
  
reply

K **Khyati** 3 years ago  
Excited to join this  
  
reply

**Melanie Ortiz** 3 years ago